



The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma: A Pathogenesis

Anna M. Czarna ¹ · Anna M. Czarna ¹ · Daniela Ma ^{1,2} · Łukasz S ^{1,3} · Fei Lia ⁴ · Anna K ^{1,2,5} · Ewa Ba ^{3,6} · Wojciech K ⁷ · Cezary Kieda ⁸ · Cezary S ¹

Published online: 26 July 2015

© The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract The *cancer stem cell* (CSC) model has recently been approached also in renal cell carcinoma (RCC). A few populations of putative renal tumor-initiating cells (TICs) were identified, but they are indifferently understood; however, the first and most thoroughly investigated are CD105-positive CSCs. The article presents a detailed comparison of all renal CSC-like populations identified by now as well as their presumable origin. Hypoxic activation of hypoxia-inducible factors (HIFs) contributes to tumor aggressiveness by multiple molecular pathways, including the governance of immature stem cell-like phenotype and related epithelial-to-mesenchymal transition (EMT)/de-differentiation, and, as a result, poor prognosis. Due to intrinsic von Hippel-Lindau protein (pVHL) loss of function, *clear-cell* RCC (ccRCC)

develops unique pathological intra-cellular pseudo-hypoxic phenotype with a constant HIF activation, regardless of oxygen level. Despite satisfactory evidence concerning pseudo-hypoxia importance in RCC biology, its influence on putative renal CSC-like largely remains unknown. Thus, the article discusses a current knowledge of HIF-1 α /2 α signaling pathways in the promotion of undifferentiated tumor phenotype in general, including some experimental findings specific for pseudo-hypoxic ccRCC, mostly dependent from HIF-2 α oncogenic functions. Existing gaps in understanding both putative renal CSCs and their potential connection with hypoxia need to be filled in order to propose breakthrough strategies for RCC treatment.

Keywords Renal cancer · *Cancer stem cells* · Hypoxia-inducible factors (HIF-1 α , HIF-2 α) · von Hippel-Lindau protein (pVHL) · Epithelial-to-mesenchymal transition

✉ Anna M. Czarna
anna.czarna@gmail.com

- ¹ Department of Oncology with Laboratory of Molecular Oncology, Military Institute of Medicine, Szaserow 128, 04-141 Warsaw, Poland
- ² School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland
- ³ Institute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, Warsaw, Poland
- ⁴ Emory School of Medicine, Atlanta, GA, USA
- ⁵ Department of General Surgery and Transplantology, Medical University of Warsaw, Warsaw, Poland
- ⁶ Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland
- ⁷ Department of Otolaryngology, Czerniakowski Hospital, Medical University of Warsaw, Warsaw, Poland
- ⁸ Centre de Biophysique Moléculaire, CNRS UPR 4301, Orléans, France

Abbreviations

CSC	<i>Cancer stem cell</i>
RCC	Renal cell carcinoma
TIC	Tumor-initiating cell
HIF	Hypoxia-inducible factor
EMT	Epithelial-to-mesenchymal transition
pVHL	von Hippel-Lindau protein
ccRCC	<i>Clear-cell</i> renal cell carcinoma
INF- α	Interferon- α
IL	Interleukin
RTK	Receptor tyrosine kinase
mTOR	Mammalian target of rapamycin
TPC	Tumor-propagating cell
HSC	Hematopoietic Stem Cell
MSC	Mesenchymal Stem Cell
Pax-2	Paired box 2

CK	Cytokeratin
SCID	Severe combined immunodeficiency
TGF	Transforming growth factor
MVs	Microvesicles
CXCR-4	CXC chemokine receptor-4
HSP	Heat shock protein
SP	Side population
Rh123	Rhodamine 123
ALDH	Aldehyde dehydrogenase
HEK	Human embryonic kidney
CTR2	Cooper transporter 2
ARNT	Aryl hydrocarbon receptor nuclear translocator
Cul2	Cullin 2
Rbx1	RING-box 1
PHD	Prolyl hydroxylase domain-containing enzyme
CBP	CREB-binding protein
HRE	Hypoxia-responsive element
TSG	Tumor-suppressor gene
LOH	Loss of heterozygosity
CpG	Cytosine-guanine dinucleotide
ROS	Reactive oxygen species
iPSC	Induced Pluripotent Stem Cell
ESC	Embryonic Stem Cell
ABC-Ts	ABC transporter
hTERT	Human telomerase reverse transcriptase
SCD1	Stearoyl-CoA desaturase-1
Akt	Protein kinase B
EGF	Epidermal growth factor
FGF	Fibroblast growth factor
PDGF	Platelet-derived growth factor
TNF- α	Tumor necrosis factor- α
EPO	Erythropoietin
PI3K	Phosphoinositide 3-kinase
VEGF	Vascular endothelial growth factor
T β RII	TGF- β receptor II
ALK	Activin receptor-like kinase
MAPK	Mitogen-activated protein kinase
ERK	Extracellular-signal-regulated kinase
Smad	Mothers against decapentaplegic
IGF	Insulin growth factor
MMPs	Matrix metalloproteinases
FAK	Focal adhesion kinase
ECM	Extracellular matrix
VM	Vasculogenic mimicry
SDF-1 α	Chemokine stromal cell-derived factor-1 α
VEGFR	VEGF receptor
PDGFR	PDGF receptor
ITPP	Inositol trispyrophosphate
EndoMT	Endothelial-to-mesenchymal transition
CAF	Cancer-associated fibroblast
rhEPO	Recombinant EPO
EPOR	EPO receptor
NICD	Notch intracellular domain

I d e i

According to *Cancer Statistics, 2015*, RCC will be responsible for 5 % of all malignancies in men and 4 % in women in the USA. RCC is characterized by a high index of advanced stages at diagnosis (17 % for regional/locally advanced and 16 % for metastatic stage) and a high mortality (5-year survival rate for metastatic disease of only 12 %) [1]. In addition, tumor recurrence occurs in 40 % of patients after curative surgical resection. Moreover, RCC is resistant to chemotherapy and radiation, and weakly sensitive to immunotherapeutic agents such as INF- α and IL-12. But in recent years, the discovery of new molecular and cytogenetic markers has led to the recognition and classification of several novel subtypes of RCC [2] and to the introduction of targeted therapies for metastatic stage RCC, including RTK and mTOR kinase inhibitors [2, 3]. However, complete responses are rare, thus, RCC is still a tumor of unpredictable presentation and poor prognosis [3]. Therefore, future studies have to provide more information concerning molecular and cellular mechanisms underlying RCC development and resistance to targeted therapies.

RCC denotes a set of cancers with diverse genetic and histopathological features, clinical course, and response to therapy. RCC is considered to originate from the highly heterogeneous renal tubular epithelium. Depending on a specific microanatomical site of malignant transformation, a resulting tumor displays unique characteristics, allowing for relatively straightforward identification in most cases [4, 5]. In the Heidelberg classification, ccRCC is the most common histological subtype of RCC [2]. According to the long-standing clonal evolution model, a recent breakthrough multiregional genetic analysis of four RCCs provided evidence of intra-tumor heterogeneity in each tumor, with spatially separated heterogeneous somatic mutations and chromosomal abnormalities (allelic imbalances and ploidy aberrations), that supplies evolutionary reservoir of phenotypic tumor cell diversity through Darwinian selection, predicting therapeutic failure due to adapted aggressive drug-resistant clones of malignant cells. In addition, a single tumor-biopsy specimen was found to contain a non-representative minority of genetic aberrations that are present in an entire tumor, therefore, intra-tumor heterogeneity may explain difficulties in the validation of molecular biomarkers essential in personalized oncology [6]. The novel CSC or TIC or TPC model introduces an additional explanation, suggesting that intra-tumor heterogeneity may also result from functional diversity among cancer cells in different states of aberrant differentiation [7, 8]. Although two essential paradigms of cancer propagation – the clonal evolution and CSC model – were originally presented as mutually exclusive theories of intra-tumor heterogeneity, they can be easily reconciled and are both an integral part of cancer development and evolution,

because in the context of the clonal evolution concept, altered tumor cells with stem cell-like characteristics may well be important units of selection [7–13]. *CSCs* are characterized by an extraordinary capacity for tumor initiation and maintenance due to unlimited self-renewal and multilineage differentiation (multipotency) towards heterogeneous progeny. Possible analogies with normal stem/progenitor cells are still being investigated [8–11].

Following a developmentally hierarchical concept of tumor generation resulting from genetic and/or epigenetic alterations of a very small compartment of normal adult somatic tissue-resident stem/progenitor cells, as described in a number of solid malignancies (breast [14], brain [15], colorectal [16], pancreatic [17], hepatic [18], lung [19], prostate [20], ovarian [21], endometrial cancer [22], malignant melanoma [23], and others), only a few diverse studies, reviewed in chapter 2 and Table 1, have focused on the identification of putative *CSCs* in RCC. These experimental results indicate that different cell subpopulations with stem cell-like properties may be present within this heterogeneous and aggressive tumor. No generally applicable markers are known so far, thus, characterization of putative renal *CSCs* is mainly based on functional studies. What is important, scientists should be aware of the existence of potential multiple, unappreciated and largely unavoidable observational errors in methodology used to study renal TICs. In view of these previously unexplored methodological biases, re-examination of the *CSC* hypothesis in other solid tumors is probably warranted [24].

Hypoxia, through the activation of HIFs, leads to adaptive changes within a cancer cell, followed by aggressive behavior which contributes to tumor progression and treatment resistance, and, as a consequence, determines an unfavorable prognosis. The correlation of intra-tumor hypoxia with a poor prognosis might be related to the increase in immature, highly aggressive and therapy-resistant malignant cells with stem cell-like characteristics [25–29]. Data reviewed in chapter 3 show this phenomenon for a number of solid tumors, both cell lines and cells directly obtained from patient-derived specimens, but the exact role played by hypoxia in *CSC*-like phenotype promotion began to be appreciated scarcely a few years ago and is still not fully known. In view of its unique pathological intracellular pseudo-hypoxic (mimicking hypoxia) phenotype due to a biallelic loss of pVHL function in the absolute majority of clinical cases, with a constitutive HIF-overactivation even in normoxic conditions [2], ccRCC appears as one of the most malignant solid tumors. The exact role of hypoxia in the governance of individual identified putative renal *CSC* populations was not studied, despite quite substantial knowledge concerning HIF activity, especially HIF-2 α oncogenic actions, in RCC development and progression. There are also a few findings documenting the hypoxic-induction of HIF-1 α -dependent, de-differentiation- and metastasis-associated EMT in RCC. Finally, some putative renal *CSC* markers are activated

by hypoxia and possibly contribute to tumor aggressiveness and stem cell functions (see chapter 3 and Fig. 3).

In conclusion, the review analyzes the existing data from both a growing field of *CSCs* and hypoxia, with the emphasis on the most recent studies, and tries to provide a potential, preliminary link between the pseudo-hypoxic and immature *CSC*-like phenotype in RCC (see Fig. 2). Filling gaps in understanding this indifferently studied relationship in RCC is necessary to overcome current treatment limitations by translation of novel discoveries into selective and efficient breakthrough therapies significantly improving prognosis.

The *CSC* Model in RCC

CD133⁺ Renal Adipogenic Progenitor Cells

CD133 (prominin-1) is a marker commonly used to define *CSC* populations. It is a five transmembrane domain-glycoprotein, in human first isolated from HSCs, expressed on various types of stem/progenitor cells and differentiated cells, but its biological function is still ambiguous [30]. Two glycosylated renal stem/progenitor cell-associated CD133 epitopes are recognized by monoclonal antibodies – CD133/1 (clone AC133) and CD133/2 (clone 293C3) [31]. Upon *CSC* differentiation, the AC133-specific epitope, but not the entire CD133 protein, is lost [32]. Prominin-1 was investigated as a marker for identification of renal TICs. A very rare population (less than 1 % of total tumor cells) of CD133⁺/CD34⁺ cells was found in human RCC using magnetic bead separation [33]. This population expressed surface markers typical for MSCs [34], such as CD29, CD44 and CD73, the mesodermal marker vimentin, and the embryonic kidney developmental stem cell marker Pax-2 which suggests renal origin. Moreover, CD133⁺ cells could undergo epithelial and endothelial differentiation both in vitro and in vivo. However, they were not able to form carcinomas after subcutaneous injection into SCID mice, indicating no tumorigenic potential [33]. This result is in contrast with the idea that, as in the case of *CSCs* derived from other organs, RCC *CSCs* arise from renal progenitors expressing the CD133 marker [35]. Because of the potential of CD133⁺ cells for in vivo endothelial differentiation in SCID mice, they were suggested to play a pivotal role in tumor vasculogenesis. First, these cells, cultured in the presence of tumor supernatant, differentiated into endothelial cells, suggesting that the tumor microenvironment could be involved in their endothelial commitment. Furthermore, CD133⁺ cells, when co-transplanted with cancer cells at the same ratio as in RCC, significantly enhanced tumor engraftment, growth and vascularization – probably by the production of cancer progression-favoring growth factors [33]. This phenomenon cannot be linked to the cancerous nature of tumor-derived CD133⁺ cells, because the same results were

Tab e 1 In vitro and in vivo properties of various putative CSC-like subpopulations identified within RCC of adults

Identification method	Markers			Functional analyses								
	CD105	CXCR-4	DNAJB8	SP				Spheres		ALDH		
Study	Bussolati et al. [47]	Gassenmaier et al. [56]	Nishizawa et al. [57]	Addla et al. [61]	Oates et al. [65]	Huang et al. [66]	Lu et al. [67]	Zhong et al. [58]	Lichner et al. [59]	Debeb et al. [70]	Wang et al. [71]	Ueda et al. [72] ⁹
MSC markers (excluding CD105) in vitro	+	+	ND	+ ²	ND	ND	ND	+ ⁴	+ ⁷	+ ⁸	ND	+ ¹⁰
MSC marker CD105 in vitro	+	+/- ¹	ND	ND	ND	ND	–	+/- ⁵	ND	ND	ND	–
<i>Stemness</i> markers in vitro	+	+	ND	+	+	ND	ND	+	+	+	+	+
CD133 marker in vitro	–	–	ND	+/- ³	ND	ND	ND	+ ⁶	ND	ND	ND	ND
ALDH activity in vitro	ND	ND	ND	ND	ND	ND	ND	ND	ND	+	+	+
SP in vitro	ND	ND	+	+	+	+	+	+	ND	ND	ND	+
Sphere formation in vitro	+	+	ND	+	ND	ND	ND	+	+	+	ND	+
Clonogenicity in vitro	+	+	ND	+	+	+	+	+	+	+	+	+
Self-renewal in vitro	+	+	ND	+	+	+	ND	+	+	+	+	+
Drug resistance in vitro	ND	+	ND	ND	ND	+	ND	+	ND	ND	ND	+
Radioresistance in vitro	ND	ND	ND	ND	ND	+	+	+	ND	+	ND	+
Tumor initiation (tumorigenicity) in vivo	+	+	+	ND	ND	+	+	+	+	+	+	+
Recapitulation of a tumor of origin (phenocopy) in vivo	+	+	ND	ND	ND	+	ND	+	+	+	+	ND
Generation of serially transplantable tumors in vivo	+	ND	ND	ND	ND	+	ND	ND	ND	+	ND	ND
Endothelial differentiation in vitro and/or in vivo (multipotency) / VM	+	ND	ND	ND	ND	ND	ND	ND	+	ND	ND	ND

ND not determined

¹ A major subpopulation within CXCR-4⁺ sphere cells derived only from established cell line SK-RC-17, not from primary cell lines² The CD44 and CD29 MSC markers (however, no significant difference compared to non-SP cells)³ Significantly higher cell number in SP than in non-SP cells, however, lower cell number than in the SP of the normal kidney⁴ The CD44 MSC marker, along with CD24 (however, no significant difference compared to non-sphere cells)⁵ Expressed on nearly all non-sphere cells, however, significantly reduced expression on sphere-forming cells⁶ No significant difference compared to non-sphere cells⁷ The CD44 MSC marker, along with CD24⁸ The CD44 MSC marker⁹ Significantly higher ALDH activity in SP than in non-SP cells only in the case of ACHN cell line (ALDH⁺ SP ACHN CSCs)¹⁰ The CD90 MSC marker (however, no significant difference compared to non-SP cells)

obtained with normal human renal tubular CD133⁺ progenitors [36]. In addition, CD133⁺ RCC cells exhibited the same progenitor phenotype as their normal counterparts, thus, they may represent tumor-infiltrating residents of the normal adult kidney [33]. Normal adult multipotent CD133⁺/CD24⁺ progenitor cell subpopulations were isolated from both tubular epithelium [36–38] and parietal glomerular epithelium of the Bowman's capsule [38–40] within the renal cortex, whereas in the inner medulla they were detectable in the Henle's loop and its thin limb segments [41]. Embryonic multipotent CD133⁺/CD24⁺ renal progenitors were also identified [42, 43]. Genomic analysis of normal renal tubular and glomerular multipotent CD133⁺/CD24⁺ progenitor cells revealed no significant differences in gene expression patterns which confirms genetic homogeneity [38].

To sum up, CD133⁺ cells, isolated from RCC, seem to be non-tumorigenic and represent resident adult kidney progenitors which may differentiate into endothelial cells forming new blood vessels in vivo in SCID mice, supporting tumor development [33]. However, a precise function of CD133⁺ progenitors in renal carcinogenesis requires more studies.

Potential Role of CSCs

CD105 (endoglin), a surface transmembrane molecule, acts as a part of the receptor for TGF- β 1/3, a pleiotropic cytokine regulating different cellular functions including proliferation, differentiation and migration. Endoglin is a hypoxia-inducible protein expressed abundantly by angiogenic endothelial cells, therefore, it is speculated to be involved in hypoxia-initiated neo-vascularization [44–46]. Bussolati et al. [47] isolated a subpopulation of putative TICs using CD105 magnetic cell sorting of renal carcinomas, independently from a histologic type of origin. In addition, CD105⁺ TICs were found in rhabdoid meningioma [48] and osteosarcoma (the CD44⁺/Stro-1⁺/CD105⁺ population) [49]. CD105⁺ TICs, isolated by Bussolati et al., represented less than 10 % of the tumor. The phenotype of in vitro analyzed CD105⁺ cells revealed several stem cell properties: expression of a set of MSC markers, such as CD44, CD90, CD146, CD73, CD29, and the mesodermal marker vimentin; expression of embryonic stem cell markers, such as Nanog, Oct4, Musashi, Nestin, renal Pax-2, and concurrent lack of differentiative epithelial proteins such as CK; growth in non-adhesive spheres; clonogenic ability; self-renewal ability; differentiation potency (in differentiating conditions) into tumor components carrying specific differentiative epithelial and endothelial markers and lack of stem cell antigens. A low number of CD105⁺ cell clones were able to generate serially transplantable carcinomas in SCID mice containing a small fraction of the undifferentiated CD105⁺ tumorigenic cell population and a lot of differentiated CD105[−] cells. CD105[−] cells did not induce tumors, indicating the tumor propagating potential of CD105⁺ cells. CD105⁺

clones, originating from transplanted tumors, displayed the same phenotype as primary clones. Re-established RCCs recapitulated the histological pattern of the heterogeneous tumor of origin, reflecting the differentiation capability of CD105⁺ cells. Evidence of in vivo endothelial differentiation of CD105⁺ clones was confirmed by the human origin of blood vessels after RCC xenotransplantation. On the basis of this, renal TICs are thought to contribute to intra-tumor vascularization [47], therefore, angiogenesis in RCC might be supported not only by endothelial cells recruited from adjacent vessels or circulating CD133⁺ progenitors [33]. In vivo endothelial differentiation was also shown for TICs derived from glioblastoma [50] as well as hepatocellular [51], ovarian [52] and breast carcinoma [53], and seems to be rather a general phenomenon of these cells [35]. It should be noted that in vivo differentiation of TICs into endothelial cells suggests a complex connection between tumor and its microenvironment. Emerging evidence indicates that TICs coordinate tumor promotion (growth, angiogenesis, metastatic diffusion) through their interactions with *niche* by two-directional release of some extracellular factors – providing TIC maintenance on the one hand, and tumor progression on the other. Besides soluble factors, tumor MVs (exosomes) emerged as potential candidates for cell-to-cell communication. MVs may reprogram target cells by transferring various bioactive molecules and initiating epigenetic changes, including membrane receptors, proteins, lipids and RNAs [3]. MVs released from CD105⁺ RCC cells promoted in vitro and in vivo tumor angiogenesis – probably by carrying pro-angiogenic mRNAs and miRNAs that were absent in those derived from CD105[−] differentiated tumor cells. Additionally, MVs favored lung metastases by inducing lung local expression of pre-metastatic *niche* formation enhancing factors [54]. In subsequent research, CD105⁺CSC-derived MVs promoted persistent phenotypical changes in mesenchymal stromal cells supporting tumor progression in vitro (migration, matrix remodeling, angiogenesis and production of growth-stimulating cytokines) and in vivo (proliferation and vascularization) [55].

Gassenmaier et al. [56] used a novel approach to identify putative CSC markers in RCC by comparing expression of a number of candidate cell surface proteins in two primary cell lines derived from two tumors with different aggressiveness – a slowly progressing localized and rapidly progressing metastatic stage disease. This was reflected by long and short survival of patients, respectively, as well as by different tumorigenic potential in immunocompromised mice and sphere-forming capacity of analyzed cell lines, suggesting differences in the content of TICs. CXCR-4 was found to be the most reliable CSC marker. A CSC-like subpopulation expressing CXCR-4 was presented at a higher level (5 % comparing to 0.8 %) in the more aggressive cell line (a metastatic stage), and enriched in tumor spheres derived from both primary cell lines and one established cell line SK-RC-17. CXCR-4⁺CSCs vs.

CXCR-4⁺ cells had a stronger sphere-forming ability and tumorigenicity. Compared to adherently grown cells, CXCR-4⁺ CSCs from derived spheres expressed *stemness* proteins (Oct4, Sox2 and Nanog) at elevated levels, had a reduced level of epithelial CK (more immature mesenchymal phenotype), and were more resistant to anti-angiogenic RTK inhibitors Sunitinib, Sorafenib and Pazopanib. Being considered to drive RCC progression and metastasis, a high content of CXCR-4⁺ CSCs, estimated by the amount of CXCR-4 expression, correlated with a worse prognosis (strong prognostic power for patients without metastases at the time of diagnosis). Importantly, CXCR-4 function was needed for maintenance of this CSC population (sphere-forming capacity). The above data may suggest that highly tumorigenic CXCR-4⁺ cells residing within both primary RCC cell lines represent the CSC-like population. In contrast to results from Bussolati et al. [47], the CD105 marker was only marginally co-expressed in the CXCR-4⁺ cell population in spheres from both primary cell lines. However, CD105⁺ cells represented a major subpopulation within CXCR-4⁺ sphere cells derived from established RCC cell line SK-RC-17. This may indicate that CD105 is not essential for RCC initiation or marks a rare, highly tumorigenic subpopulation of putative renal CSCs only in some primary tumors or established cell lines, thus, is not suitable for the identification of CSCs in each experimental approach. On the other hand, expression of CD133 was restricted to a small fraction of cells which number did not increase with tumor sphere formation [56].

In addition, Nishizawa et al. [57], using two RCC cell lines, demonstrated that the overexpression of the HSP40 family member, DNAJB8, increased the percentage of SP cells and enhanced their tumor-initiating ability. Conversely, DNAJB8 attenuation declined the percentage of SP cells and reduced tumorigenicity. This observation indicates that DNAJB8 contributes to CSC-like phenotype of RCC and appears as a new antigen of renal CSCs.

As the identification of CSC selective markers is not always easy, the culture system could be useful for functional selection and enrichment of TICs by exploiting their ability to generate spheres [3]. Cells growing in suspension as tumor spheres in serum-free medium, supplemented with growth factors, were isolated from SK-RC-42 RCC cell line by Zhong et al. [58]. The sphere-forming population showed the *stemness* potential of CSCs, in contrast to monolayer adherent cells – higher in vitro levels of several stem cell markers (Oct4, Nanog, β -catenin, BMI), ability for self-renewal, stronger tumorigenicity, and resistance to chemotherapeutic agents and irradiation. Furthermore, the immunophenotype of sphere-forming renal CSCs suggests that they may play an important role in the evasion of tumor growth from immune surveillance. In contrast, no significant differences were found between monolayer adherent and sphere-forming cells for expression of CD44, CD24 and CD133 markers. Surprisingly,

the CD105 marker was expressed on nearly all non-sphere cells, but its expression on sphere cells was significantly reduced. Therefore, data obtained in this study do not definitively address the issue of a relative frequency of CSCs in SK-RC-42 sphere-forming and monolayer adherent cells. In addition, Lichner et al. [59] isolated RCC spheres exhibiting CSC-like properties coupled to TGF- β -EMT axis, including clonogenicity, self-renewal capacity, tumorigenicity, the ability to differentiate to cell types of the tumor of origin as well as increased expression of stem cell-related transcription factors (Oct4, Nanog, Klf4 and LIN28).

Another functional approach of renal CSC isolation was performed by the identification of cells appearing as the SP [60] from both normal and malignant tubular epithelial cells of the nephron, using cytofluorimetric evaluation of Hoechst 33342 dye uptake [61]. This efflux assay, first developed in the hematopoietic system, allows for the selection of a cell population that rapidly extrudes dyes due to specific membrane transporters typically associated with *stemness* [62]. Addla et al. [61] demonstrated about 4 % of normal kidney cells and about 6 % of RCC cells could be defined as the SP. The SP of RCC exhibited in vitro sphere-forming capacity and enhanced proliferative potential as well as expressed more widely β -catenin, Notch, Sonic Hedgehog and Pax-2 stem cell markers, as compared to non-SP RCC cells. However, RCC SP cells were noted both in G₁ (most of cells) and G₀ (quiescent) phase, indicating heterogeneity of this population and suggesting that the terms SP and CSC perhaps cannot be used interchangeably, but further studies are needed. Indeed, researchers still question the full relationship between SP cells and CSC-like phenotype [60]. For example, the SP of glioblastoma multiforme does not necessarily contribute to self-renewal and tumorigenicity related to CSCs [63]. These questionable interpretations suggest that the reliability and reproducibility of the SP assay regarding to CSCs are the challenge and should be improved [64]. Differential expression of the CD133 marker between the SP of the normal kidney and RCC was found (15 and 3 %, respectively) [61]. The SP of the normal kidney expressed the same markers as identified in renal CD133⁺ progenitors by Bussolati et al. [36]. According to the RCC SP, above-mentioned results were confirmed in subsequent research of this group [65]. In addition, Huang et al. [66] identified SP cells of 769P RCC cell line (4.8 %). The 769P SP cell fraction possessed the CSC-like characteristics, including the ability for increased proliferation, self-renewal and differentiation as well as strong resistance to chemotherapy (related to the ABCB1 transporter) and radiotherapy. Moreover, Lu et al. [67] identified two SP cell subpopulations within cultured 786-O RCC cell line – Rh123^{high} and Rh123^{low}. Rh123^{high} cells were the minority among 786-O cells, exhibited a noticeably higher proliferative activity, long-term differentiation potential and resistance to radiation as well as enhanced colony-forming efficiency and

tumorigenic potential, compared to Rh123^{low} cells, thus, may be regarded as a novel *CSC*-like cell population of RCC. However, CD105 marker expression was not observed on the surface of 786-O cells. Furthermore, the characterization of RCC SP cells with the high brilliance synchrotron-FTIR spectroscopy revealed the presence of their various subpopulations with diverse biochemistry, but there is neither evidence of a differential role of particular subpopulations in carcinogenesis, nor were any specific set of markers identified [68].

Based on the utility of high ALDH enzymatic activity for the functional identification of *CSCs* [69], Debeb et al. [70] studied cancer cells with stem-cell like features belonging to the HEK 293 T population. HEK 293 T cells, cultured in vitro as 3D spheres in serum-free stem cell-promoting culture conditions, exhibited *CSC*-like phenotype – they contained the larger CD44⁺/CD24⁻/ALDH⁺ cell population compared to cultured monolayer cells, displayed upregulated stem cell survival signaling, including β -catenin, Notch and survivin, had increased expression of several mesenchymal, pro-metastatic EMT-related genes, and were radiation-resistant. Serial xenografts of HEK 293 T cells into immunocompromised mice yielded aggressive, self-renewing tumors. These findings suggest that HEK 293 T is a valuable cell line to study the plasticity of transformed embryonic cells, thus, representing an important research tool for studying molecular mechanisms in putative renal *CSC* maintenance. Strongly tumorigenic renal ALDH⁺*CSC*-like cells were also identified by Wang et al. [71] by the use of the xenograft model of ACHN (pleural effusion metastasis) and Caki-2 RCC cell lines. Isolated cells displayed several stem cell-like properties in vitro, including clonogenic and self-renewal ability, and increased expression of Oct3/4A, Nanog and Pax-2 stem cell markers. In vivo experiments showed that cells with a high ALDH activity had greater tumorigenicity compared to their counterparts with a low ALDH activity, generating new tumors with as few as 25 cells. In addition, Ueda et al. [72] used the combination of two functional approaches, the SP approach and ALDH enzymatic approach, to identify the *CSC*-like population residing within ACHN and KRC/Y RCC cell lines. SP fractions in ACHN and KRC/Y were 1.4 and 1.7 %, respectively. ACHN SP cells revealed a significantly stronger ALDH activity than non-SP cells (about 33 % and about 15 %, respectively). ALDH⁺ ACHN cells had a stronger sphere-forming and self-renewal ability as well as showed enhanced expression of *CSC*-related genes (*stemness*, drug efflux transporter, anti-apoptotic, angiogenic and EMT-related genes) and higher tumorigenic potential in SCID mice compared to non-SP cells with lower ALDH activity. Importantly, whereas ACHN SP cells showed a stronger sphere-forming ability and drug resistance (INF- α) compared to non-SP cells, the tumorigenic ability was only slightly higher, suggesting that only ALDH⁺ cells within the SP population rather than all SP cells possess real *CSC*-like properties. In the second cell line analyzed, KRC/Y, there was no

difference in ALDH expression between SP and non-SP cells. Intriguingly, this study found that while SP cells of KRC/Y cell line contained about five times more CD105⁺ cells than non-SP cells, there were no differences in *CSC*-like properties between SP and non-SP cells, therefore, KRC/Y SP cells lack this characteristics. In turn, within more aggressive ACHN cell line, the CD105 marker was expressed only in a few cells. Thus, these results are in conflict with the findings of Bussolati et al. [47], regarding the CD105⁺*CSC* population, and suggest that CD105 may not be a universal *CSC*-related

embryonic renal epithelial [36–43] as well as in corresponding non-tumorigenic tumor-derived CD105⁺ progenitor cells [33]. Thus, it is suggested that putative renal CSCs do not originate from CD133⁺ renal progenitors, but rather from a yet undefined, undifferentiated kidney-resident adult CD105⁺ stem cell population retaining mesenchymal phenotype, possibly that studied by Bruno et al. [76]. This is in contrast with the idea of RCC originating from CD133⁺ cells, as in other tumors [30]. Alternatively, CD133⁺ cells are very few in the non-SP population of normal kidney as well as in SP and non-SP RCC cells, compared to the SP of the normal kidney (however, CD133 was not present on presumable normal kidney stem cells, isolated by Bruno et al. [76]), pointing the loss of the CD133 marker which could be a very early event in stem cell differentiation and possibly in malignant transformation. This finding is also in opposition to the common notion that CD133 is a definitive stem cell marker in solid tumors [61]. In line with this, another well described putative renal CSC population, CXCR-4⁺, did not express CD133 [56] as well as marker expression on sphere-forming cells vs. adherent cells was not specific [58]. Moreover, CD133 expression was evaluated on samples of human RCC, using the stem cell-specific anti-human-CD133/1 (AC133) monoclonal antibody recognizing the glycosylation-dependent epitope of prominin-1, but no correlation with pathological changes and affected patient prognosis was found [82]. Additionally, an immunohistochemical study of highly differentiated, non-metastatic and Oct4-negative ccRCC revealed high CD133 expression, suggesting that it is a favorable prognostic marker [83]. In contrast to above-mentioned results, a stable transfection of CD133 into HEK293 cells induced their in vivo tumor-initiating properties [84]. In this scenario, Gallegiante et al. [85] has recently described a ccRCC-derived CD133⁺/CD24⁺/CTR2⁺ cell population. It showed some stem cell-like properties similar to those of CD133⁺/CD24⁺ tubular progenitors from the healthy kidney, including in vitro self-renewal and multipotency, and in vivo angiogenic potential, but no expression of MSC markers. Comparing to their non-neoplastic counterparts, CD133⁺/CD24⁺/CTR2⁺ cells could regenerate tumor in vitro in soft agar (small colonies), were more undifferentiated (expressed higher embryonic stem cell marker levels), and had an individual gene expression profile, in particular, CTR2 was identified as a cell membrane protein involved in cisplatin chemoresistance that could be used to discriminate this population from normal progenitors. Furthermore, a very recent study of Varna et al. [86] indicated the enrichment of tumorigenic CD133/CXCR-4-co-expressing cells, considered CSCs by the authors, in perinecrotic vs. perivascular areas of primary metastatic RCCs and their xenografts.

In the kidney, which has lower cell turnover compared to highly proliferating organs such as the gastrointestinal tract and skin [4, 35], the evaluation of putative stem cells is fastidious and their role in tissue repair is less evident. It is important to note that the CSC theory is mainly based on functional approaches. As a result, TICs do not necessarily have to be derived from normal tissue stem cells [4]. Alternatively, it could be postulated that kidney tissue lacks a true stem cell compartment [35]. First, renal tubular cells may be suggested to modulate their phenotype towards *stemness* in response to microenvironmental stimuli due to plastic cell phenotype evidenced by staying in G1 phase of the cell cycle (cyclin D1 activity) [87]. In addition, renal tubular epithelium is almost entirely quiescent in the basal state [88], but displays a considerable proliferative/regenerative capacity upon acute renal injury. This step does not involve specialized progenitors or a stem cell pool, but instead requires randomly surviving, terminally differentiated tubular epithelial cells [87, 89–91]. Thus, a mechanism of renal CSC generation, different from genetic and/or epigenetic alterations of kidney-resident stem cells, might theoretically occur, implying the de-differentiation process of mature tubular epithelial cells towards immature phenotype [4, 35]. Indeed, terminally differentiated tubular cells were shown to de-differentiate through the EMT process and actively proliferate during tubular repair [92, 93]. In breast cancer cells, the inhibition of E-cadherin, a marker strongly associated with epithelial phenotype, was demonstrated to induce mesenchymal traits and enhance self-renewal ability [94]. During regeneration, tubular re-expression of the kidney-specific marker Pax-2 supports a de-differentiation concept [95]. These observations could serve as the bridge between two models of cancer evolution in RCC – the clonal evolution and CSC model – since the de-differentiation process may occur at various stages of malignant transformation (selection of aggressive cancer cell clones) [4]. Taking into consideration a high heterogeneity of epithelial structure and a diverse differentiation state of

human recipient cell origin arising in the grafted kidney was reported, suggesting the integration in the grafted kidney of circulating cells originating in the recipient and their subsequent transformation in the graft [100]. Moreover, in vitro and in vivo multipotent differentiation of CD105⁺ TICs is consistent with the ability of mutated bone marrow MSCs to generate both tumor and tumor vasculature cells [103]. Additionally, mesenchymal cells, present in the tumor stromal microenvironment, supposedly undergo neoplastic mutations, epigenetic changes or chromosomal aberrations [104–106]. In contrast to cells forming mesenchymal tumors, renal CD105⁺ TICs expressed Pax-2 and were able to generate in vivo serially transplantable tumors being epithelial cancers (carcinomas) as a tumor of origin. Within those tumors, they gave rise to the CD105⁺ undifferentiated, tumorigenic population and CD105[−] non-tumorigenic differentiated cells, and did not differentiate into adipocytes and osteocytes [47].

In conclusion, the source of the most specifically described putative renal CD105⁺ CSCs [47, 54, 55], but also of other RCC TICs (see Table 1), may be diverse, not necessarily involving kidney-resident MSCs (see Fig. 1). A common CSC marker, CD133, is probably not associated with renal TICs [33, 47, 56, 58, 61, 82, 83], however, some findings contradict this statement [84–86]. Thus, further studies are necessary to eliminate all inconsistencies (Figs. 2 and 3).

Hypoxia in RCC Pathogenesis

Molecular Regulation of Hypoxia

Tissue hypoxia is defined as reduced oxygen partial pressure $\leq 2\%$ (≤ 15 mm Hg). Most mammalian tissues exist naturally at 2–9 % O₂ (on average 5.5 %, 40 mm Hg) [107], including renal cortex with proximal and distal tubules (7 %, 50 mm Hg). In contrast, the kidney medulla is physiologically poorly oxygenated (1.4–2.8 %, 10–20 mm Hg) [108]. Heterogeneously distributed areas with insufficient blood supply may develop within rapidly growing solid tumors and their metastases. Two types of intra-tumor hypoxia are distinguished – chronic (diffusion-limited, in tumor regions distant from blood vessels) and acute (perfusion-limited, during blood vessel occlusion) [109–111]. Hypoxia compromises cell biology due to impaired energy requiring processes [107]. Cancer cells can survive sustained oxygen deficiency as a result of a coordinated set of adaptive cellular responses to hypoxic stress which are complex processes involving large molecular networks centrally governed by HIFs – HIF-1 and HIF-2 – master regulators of oxygen homeostasis within cells. HIFs are heterodimers composed of an unstable HIF- α (HIF-1 α or HIF-2 α) subunit, tightly regulated by oxygen (hypoxia-sensitive), and a stable, constitutively expressed (regardless


of oxygen level) HIF- β subunit, also known as ARNT [107, 112–117].

pVHL, through its oxygen-dependent posttranslational polyubiquitination of HIF-1 α /2 α subunits, plays a central role in the mammalian oxygen-sensing pathway [115]. The *VHL* gene was isolated in 1993 [118] and mapped to 3p25–p26. The gene sequence is highly conserved in primates and rodents, and has homologues in *Caenorhabditis elegans* and *Drosophila melanogaster*. Sequence conservation is particularly high across regions known to be involved in pVHL binding to other proteins [119]. pVHL binds to elongin C which forms a multi-subunit complex with elongin B and Cul2/Rbx1 proteins having E3 ubiquitin ligase activity, thus, pVHL is proposed to act as the substrate recognition subunit of this complex recruiting HIF-1 α /2 α for polyubiquitination resulting in their subsequent 26S proteasome-mediated degradation. The hydroxylation of evolutionarily conserved two proline residues of HIF- α under sufficient oxygen tensions, carried out by members of the EglN prolyl hydroxylase family, also known as PHDs, creates high affinity of modified HIF-1 α /2 α to the pVHL binding site [113, 120–122]. Classically, HIF-1 and HIF-2 are regulated by rapid degradation of translated HIF-1 α and HIF-2 α subunits at normal oxygen levels (normoxia) or their stabilization in hypoxia. Decreased oxygen tensions lead to increased activity of HIF. After dimerization of HIF-1 α /2 α with the HIF- β subunit, constantly present in the cell cytoplasm, HIFs in an active state translocate to the nucleus and bind, in concert with co-activators p300 and CBP, to HREs located in promoters of their hundreds of downstream target hypoxia-inducible genes which become transcriptionally activated [107, 112, 116, 117, 123–125]. Approximately 1–1.5 % of the human genes are regulated by HIFs [126]. A less studied HIF-3 α subunit shares a DNA-binding domain with HIF-1 α /2 α subunits, but lacks a transcription activation domain. Therefore, HIF-3 α is considered to serve as a dominant negative regulator of HIF-1 α /2 α -mediated transcription by the inhibition of the binding of HIF- α subunits to promoters of their target genes [127].

ccRCC Pathogenesis – Effect of VHL Loss

The genomic 3p25 region, carrying the *VHL* gene, is commonly deleted or altered in ccRCC [128]. The *VHL* gene has a critical *gatekeeper* role in the regulation of growth and differentiation of renal tubular cells. It acts as a classic *two-hit* TSG [119], as defined by Knudson [129]. The loss of normal TSG function due to its biallelic inactivation in renal epithelium may initiate cancer development. As the *hits*, the genome of ccRCC cells generally shows deletion, mutation and methylation within both maternal and paternal loci of the *VHL* gene, in accordance with its role as a TSG [122]. A biallelic

Fig. 1 The CSC model in RCC. **a.** A general hierarchical model of tumor heterogeneity. **b.** Hypothetical cells of origin of putative renal CD105⁺ TICs. CD105⁺ cells are the first and most thoroughly studied renal CSC population identified by now [47]. The most probable cell of origin seems to be a resident renal adult multipotent CD105⁺ stem cell retaining mesenchymal phenotype (a MSC), possibly that studied by Bruno et al. [76]



loss of function of the *VHL* gene occurs in the majority of sporadic and in all heritable (familial) ccRCC cases [115, 122]. This inactivation is believed to be one of the earliest stages of renal tubular cell neoplastic transformation to ccRCC, as it is observed in pre-malignant cystic lesions of the kidney as well as in advanced tumors [122]. A functional loss of the *VHL* gene usually occurs in ccRCC [115, 122]. The restoration of *VHL* gene function in *VHL* ^{-/-} ccRCC cells is sufficient to prevent them from growing as tumors in vivo [130]. In the setting of sporadic ccRCCs, both a first and a second *hit* occur somatically. Thus, they are confined only to somatic cells of an individual, therefore, are not heritable [122]. Somatic mutations of one allele (maternal or paternal) of the *VHL* gene were observed in 42–71 % of sporadic ccRCC cases, accompanied by deletion of the second gene copy, manifested as LOH on chromosome 3p25–p26, in 73–98 % of those lesions. These mutations were heterogeneous in

type and distributed across much of the gene [131–135]. A copy of the *VHL* gene can also be epigenetically inactivated (silenced) by hypermethylation of normally unmethylated CpG in the 5' region (promoter) of the *VHL* gene in about 20 % of sporadic ccRCCs [135, 136]. The absolute majority of those ccRCC cases show methylation of one allele of the *VHL* gene and subsequent deletion of the other (LOH). Thus, DNA methylation may represent another mechanism of the *VHL* gene biallelic inactivation which seems to function identically to inactivating somatic mutations of its one allele in association with a loss of the second allele. Occasionally, both retained alleles are methylated. This methylation phenomenon was detected for a number of TSGs [136]. A loss of normal *VHL* gene function is also common in familial ccRCC associated with rare autosomal dominant VHL disease [116, 119]. Individuals with the VHL disease carry in their germline one *VHL* allele inactivated through mutation (a first *hit*) and one





Fig. 2 A putative connection between hypoxia and immature CSC-like phenotype in RCC

Fig. 3 A hypothetical HIF-1α/2α-dependent signaling crosstalk within putative renal CSCs involving pathways of three associated markers: CD105, CXCR-4 and ALDH. As a presumable oncogene, HIF-2α is supposed to drive progression of pVHL-defective, pseudo-hypoxic ccRCC (the absolute majority of clinical cases), possibly including promotion of aggressive, immature CSC-like phenotype. The figure does not represent pathways in a particular putative renal CSC population, but serves as the summary model of all known interactions in various identified populations. A few complements in signaling crosstalk were taken from [25, 168]



wild-type allele [115]. Pathological changes ensue when the wild-type allele is deleted or somatically inactivated due to hypermethylation or mutation (a second *hit*). In an individual with a germline mutation in one allele of the *VHL* gene, the probability of a second *hit* occurring somatically in the wild-type allele is much higher than the probability of two independent somatic *hits* in a normal individual. This fact explains why ccRCC in VHL patients often develops at earlier age than equivalent sporadic tumors in general population [122].

In ccRCC cells, lack of functional pVHL due to a *VHL* gene loss of function through the biallelic inactivation prevents from HIF-1 α and HIF-2 α polyubiquitination and subsequent proteasome-mediated degradation, even under normoxic conditions, allowing them to increasingly accumulate and form stable HIF-1/2 heterodimers, what results in their pathological constitutive activation. This unique intracellular pseudo-hypoxic phenotype, present as an intrinsic tumor feature, mimics intra-tumor hypoxia [2, 137, 138], contributing to dramatic phenotypic shift in expression of HIF target genes promoting tumor aggressiveness, including angiogenesis, proliferation/mitogenesis, survival/resistance to apoptosis, increased invasiveness and metastatic potential, glycolytic metabolism and extracellular acidosis, hence, determining a poor outcome [107, 111, 112, 117, 125, 139–142].

Hypoxia Effect on CSC-Like Phenotype in RCC – General Specific Evidence

CSC-Related Pathways

CSC-associated genes are also being considered HIF-target. Both long-standing and emerging data show an effect of hypoxia on the maintenance of normal embryonic and multiple adult stem cell populations [26, 27, 29, 143–147]. The reason why hypoxia stimulates stem cell maintenance is largely unknown, but one attractive hypothesis assumes stem cell localization in the low oxygen microenvironment to reduce DNA damage resulting from ROS-associated genotoxic oxidative stress [29, 148]. Most colon CD133⁺CSCs are located in hypoxic *niche* protecting them from chemotherapy [149]. CSCs within several brain tumors preferentially locate in hypoxic [150, 151] or pseudo-hypoxic (HIF-2 α) perivascular (oxygenated) *niche* [151–155]. Hypoxia promotes self-renewal capability and inhibits differentiation of glioma/glioblastoma CSCs [154–156]. Glioma CSCs, cultured in the presence of oxygen partial pressure lower than 2 %, display less spontaneous differentiation than when cultured in 21 % oxygen [154]. Reduction in oxygen tension in spheroid cell cultures established from glioma dramatically increases the percentage of cells expressing the CD133 CSC marker [155, 157], but also enhances their stem cell-like phenotype (Oct4, Sox2 and Nestin expression) [155]. HIF-2 α is believed to play a central role in CSC maintenance in hypoxia. Compared to

HIF-1 α , which is expressed both in glioma/glioblastoma CSCs and non-stem cancer cells in hypoxia, HIF-2 α has a unique expression pattern – it is highly induced only in CSCs [154, 158]. In this line, HIF-2 α overexpression in glioblastoma cells promotes CSC-like phenotype and significantly increases tumorigenicity [158]. However, both HIF-1 α /2 α were shown to be critical for CSC maintenance, as the knockdown of either HIF-1 α or HIF-2 α reduced self-renewal capacity, enhanced differentiation, attenuated tumorigenicity and increased apoptosis of glioma/glioblastoma and neuroblastoma TICs, resulting in less aggressive tumor phenotype [153, 154, 156, 158]. Interestingly, HIF-2 α is not expressed in normal neural stem cells, making it a very attractive target for CSC drug development [154].

Hypoxia was shown to modulate critical, specific signaling pathways, that control the capacity for self-renewal, multipotency/differentiation and proliferation of CSCs. Molecular links between HIFs and these key regulatory factors confirm the emerging concept that HIFs not only act in metabolic adaptations of cancer cells, but can also control their immature phenotype. A broad spectrum of activities, influenced by HIFs, overlaps with pathways affected by c-Myc, a crucial oncogenic transcription factor. These interactions can influence tumorigenesis of several cancers [159], including ccRCC. In this tumor, HIF-1 α /2 α appear to have contrary effects on c-Myc. Whereas HIF-1 α counteracts c-Myc pathways in cell cycle arrest (proliferation inhibition) of pVHL-deficient, pseudo-hypoxic ccRCC [160] as well as of colon carcinoma [161], HIF-2 α promotes c-Myc activity in pVHL^{-/-} ccRCC [160]. HIF-dependent effects on c-Myc can be used to classify pVHL-defective ccRCC into two subtypes – HIF-2 α -expressing subtype (displaying increased c-Myc activity and faster proliferation) and HIF-1 α /2 α -expressing subtype (displaying neither enhanced nor diminished c-Myc activity due to HIF-1 α /2 α antagonism) [162]. Analogous to c-Myc, while HIF-1 α promotes p53 phosphorylation and subsequent p53-induced apoptosis upon γ -radiation, HIF-2 α inhibits them, leading to overall reduction of p53 activity under radiation resulting in radioresistance (a significant feature of CSCs). From the clinical point of view, similarly to interactions of HIFs with c-Myc, the ccRCC subtype that expresses the HIF-2 α has markedly less phospho-p53 (and develops radioresistance) compared to ccRCC subtype expressing both HIF-1 α /2 α [163]. To sum up, antagonistic effects of HIF-1 α /2 α towards c-Myc and p53 appear to influence ccRCC development and progression. In view of CSCs, this phenomenon has a great clinical significance pointing to HIF-2 α oncogenic function in ccRCC. Another stem cell factor, Oct4, was demonstrated to maintain hypoxic tumor cells in an undifferentiated state towards enhanced progression [164]. As c-Myc [160] and Oct4 [164] activation is HIF-2 α -dependent, hypoxic regulation of these two stem cell factors may powerfully impact CSC formation from cells expressing HIF-2 α .

Moreover, Oct-4 and c-Myc, along with Sox2 and Klf4, are required for the formation of iPSCs from adult fibroblasts [165], and that hypoxia enhances the generation of iPSCs [166]. In numerous cancer cell lines, including RCC cell lines, HIFs were demonstrated to induce expression of all iPSC-related markers as well as of Nanog embryonic stem cell marker [167]. Like c-Myc and Oct4, Sox2, Klf4 and Nanog are HIF-2 α -dependent [168]. The ability of the hypoxic microenvironment to potentiate the Notch pathway in lung adenocarcinoma [169], malignant melanoma [170] as well as glioma CSCs [171] was documented. Notch is a HIF-1 α -target [172], however, recent evidence also indicates a regulative role of HIF-2 α as signaling repressor [171]. In addition, Wnt/ β -catenin signaling governs CSC features in response to hypoxia [173]. In ESCs, this pathway was shown to be a HIF-1 α -target [174]. The opposite result was reported for colon carcinoma cells in which HIF-1 α inhibited Wnt/ β -catenin activity [175]. Thus, it can be suggested that the interaction between HIF-1 α and Wnt/ β -catenin is functionally distinct in various cell types. Finally, proteins regulating other crucial stem cell functions have been identified as HIF-targets. A gene encoding glycoprotein ABC-Ts, *MDR1*, which confers multidrug resistance on a variety of cancer cells, is a direct HIF-1 α -target [176]. In addition, *hTERT*, a gene encoding the enzymatic component of human telomerase that promotes immortalization of CSCs, is induced by hypoxia in a HIF-1 α dependent manner [177]. Hypoxia (HIF-1 α) may also enhance genetic instability of CSCs, favoring their undifferentiated state [143]. Furthermore, SCD1, an enzyme in the biosynthesis of monounsaturated fatty acids from saturated fatty acids, is upregulated under hypoxia and modulated by HIF-2 α in ccRCC. Upregulation of SCD1 in response to HIF-2 α enhanced HIF-2 α expression in a positive feedback loop mediated by Akt pathway [178]. Indeed, the Akt-downstream protein, mTOR, can directly activate not only HIF-1 α [142], but also HIF-2 α [179]. Synergistic effects between SCD1 and HIF-2 α contributed to tumor progression: survival (apoptosis inhibition), colony formation ability and migration capacity (metastasis) of pVHL $-/-$ 786-O cells. Once pVHL was restored, SCD1 expression became less sensitive to changes in HIF-2 α level [178]. SCD1 is also a key factor for lung spheroid-forming TICs. SCD1 upregulation in lung cancer spheroids is parallel with increased ALDH CSC marker activity [180] that was found to be associated with some renal TIC populations [70–72]. It was shown that increased ALDH activity promotes CSC-like phenotype of breast cancer through a novel mechanism involving HIF-2 α upregulation [181, 182]. Inhibition of ALDH suppressed CSC properties both in vitro and in vivo [181]. Importantly, the only study analyzing the influence of hypoxia on putative CSCs in RCC was performed on one of identified ALDH $^{+}$ population associated with SP cells (derived from pVHL $+/-$ ACHN cell line). Hypoxic treatment increased the number

of ALDH $^{+}$ cells 2–3 times; however, more detailed studies were not done [72].

De-differentiation/EMT

Beyond evidence for the maintenance of the CSC-like potential, hypoxia was indicated to directly alter gene expression of non-stem cell-like neoplastic cells, promoting their spontaneous de-differentiation towards immature stem cell-like phenotype in neuroblastoma [183], breast carcinoma [184], glioblastoma [158], ovarian cancer [185] and osteosarcoma cell lines [186]. De-differentiated malignant cells acquired CSC-like properties, including self-renewal ability [158, 185, 186], multipotency [186], tumorigenicity [158, 183, 186], invasiveness/metastatic potential [183–186] as well as expression of essential stem cell factors: Notch in neuroblastoma [183], Oct4, c-Myc and Nanog in glioblastoma [158], Oct4 and Sox2 in ovarian cancer [185], and Oct4 Sox2 and Nanog in osteosarcoma studies [186]. In ductal breast carcinoma in situ, tumor cells were less differentiated in hypoxic areas of a malignant lesion, confirming results of de-differentiation experiments on breast carcinoma cell lines [184]. In agreement with these studies, malignant melanoma cell lines may acquire CSC-like phenotype through Oct4-mediated cell de-differentiation [187]. There is a strong correlation between tumor clinical stage, differentiation status and behavior. High stage cancers are mostly immature (poorly differentiated) which makes them more aggressive than their more differentiated counterparts [188]. Hypoxia-induced cell de-differentiation contributes to cancer cell plasticity and heterogeneity, hence, has a direct clinical impact. This appears to be a general phenomenon in solid tumors and the mechanism to explain their increased aggressiveness and unfavorable outcome [189].

Molecular mechanisms ruling tumor cell de-differentiation came into focus along with the CSC concept. It is noticeable that terms *de-differentiation* and *EMT* show a considerable degree of conceptual overlap. EMT describes how epithelial cancer cells de-differentiate towards mesenchymal, fibroblastoid, spindle-shaped, apolar cells, simultaneously gaining increased motility and invasiveness [188]. EMT endows transitioned cancer cells with stem cell-like properties, providing a mechanistic link between mesenchymal phenotype, CSCs, metastatic potential and resistance to therapies [94, 126, 190–195]. An important question in this context is to what degree EMT equates to de-differentiation [188]. A set of diverse extracellular stromal (microenvironmental) signals was reported to induce EMT in malignant epithelial cells, including Wnt/ β -catenin and Notch stem cell markers, growth factors such as TGF- β , EGF, FGF and PDGF, transcription factors such as TWIST, SNAIL and ZEB, inflammation cytokines such as tumor necrosis factor- α (TNF- α) and interleukins as well as other specific molecules [191, 194–196]. EMT-

triggering mechanisms in cancer are activated by hypoxia [25, 126, 190, 191, 195, 196]. Also hypoxia-responsive EPO, overexpressed especially in ccRCC, might stimulate EMT mediated by PI3K/Akt/mTOR pathway [197].

In pVHL-defective, pseudo-hypoxic ccRCC cells, HIF-1 α deregulation was linked to the downregulation of E-cadherin and induction of EMT [198–203] – a second specific hallmark of RCC (beyond abundant angiogenesis) [142]. In addition, hypoxia occurring after renal injury may activate a de-differentiation program in tubular epithelial cells through Oct4 induction providing mesenchymal CD133⁺ progenitor phenotype which may contribute to kidney regeneration. Hypoxia contributes to increased clonogenicity, proliferation and VEGF synthesis by renal medullary progenitors. These effects are reduced by HIF-1 α downregulation and followed by progenitor epithelial differentiation [41]. Indeed, CD133 expression is strongly related to the nuclear HIF-1 α protein within 786-O RCC cell line and may be upregulated under hypoxic environment [204]. Importantly, with regard to the first and most accurately described population of putative renal CSCs, CD105⁺ cells [47], given the endoglin role in activated endothelial cells [44–46], it is not surprising that there is a positive correlation between hypoxia and CD105 protein expression – it is a HIF-1 α -target [205]. CD105, along with T β R II and ALK, is a part (a co-receptor) of TGF- β 1 receptor complex [44–46, 205, 206]. The complex is characterized by serine-threonine kinase activity [206]. Via MAPK/ERK pathway, which is Smad-independent, TGF- β 1 is supposed to crosstalk with Wnt, Notch, IGF and PDGF signaling in order to induce de-differentiation/EMT in osteosarcoma cells. TGF- β 1 expression might be activated in the MAPK/ERK-dependent autocrine loop to further promote de-differentiation [186]. Moreover, TGF- β 1-EMT axis (Smad-dependent) through T β R II is supposed to play an important role in the in vitro induction of one of sphere-forming CSC-like populations in RCC and in associated in vivo sarcomatoid de-differentiation within xenografts derived from these tumor spheres [59]. In line with the activation of TGF- β signaling, endoglin enhances the invasiveness of brain metastatic breast tumor cells by induction of MMPs (involved in metastasis) and chemotaxis to TGF- β from metastatic site [207]. Ewing sarcoma and melanoma research indicates that CD105 can also contribute to tumor aggressiveness independently from TGF- β (inhibition). Endoglin acts in concert with FAK and PI3K signaling to maintain in vitro plastic phenotype and invasiveness (colony- and spheroid-forming ability) as well as in vitro and in vivo growth of tumor cells, which result in poor prognosis [208]. FAK determines tumor aggressiveness by both the induction of matrix MMPs (via PI3K/Akt/mTOR pathway) and EMT [209]. Tumor cell plasticity is an alternative mechanism of tumor blood perfusion to complement the endothelial cell-dependent vasculature. It implies the possibility that some high-grade tumor cells display multipotent embryonic stem

cell-like phenotype which enables their differentiation towards abnormal endothelial-like cells forming *de novo* ECM-rich vascular-like channels. This pseudo-tubular structures mimic the pattern of embryonic vascular network, thus, is called VM [208, 210]. The VM phenomenon is induced by hypoxia [208]. The characteristics of undifferentiated cells underlying VM is not well understood [210]. Alternatively, a link between EMT, CSCs and VM was proposed. Because tubular-like cells show a significant expression of both endothelial and immature tumor phenotype, VM may represent the transitory step in incomplete CSC differentiation into endothelial cells [211, 212]. Indeed, the in vivo ability for endothelial differentiation of CD105⁺ RCC CSCs and the consequent involvement in tumor vascularization were described [47]. The presence of CSC-dependent vasculogenesis in RCC explains altered embryonic phenotype and behavior of derived endothelial cells such as chromosomal abnormalities and the independence on growth factor supply [212]. In addition, VM was found in xenografts arisen from CSC-like spheres of RCC. However, as mentioned above, TGF- β 1 signaling, potentially blocked by CD105, plays an important role in the governance of this CSC population. Nevertheless, it is unknown if these cells express CD105 [59]. In RCC, VM is an independent unfavorable prognostic factor [213]. In a few studies, in contrast, CD105 was shown to be a tumor repressor by the inhibition of TGF- β signaling [208, 214]. Thus, it is presumed that endoglin function is context-dependent, and TGF- β signaling is highly complex [208]. Finally, another putative renal TIC marker, CXCR-4, is upregulated by HIF-1 α in pVHL-defective ccRCC [82, 215, 216]. SDF-1 α -CXCR-4 axis can activate EMT/metastasis of CSCs [25].

It should be emphasized that intrinsic pVHL-deficient pseudo-hypoxic phenotype is not the common basis of cancer, except the absolute majority of ccRCC clinical cases. Somatic mutations of the *VHL* gene are extremely rare in epithelial solid tumors (including the minority of RCC clinical cases). These pVHL-wild-type tumors often contain chronic and acute hypoxic regions acquired during development. In these regions, active HIF- α subunits accumulate owing to their impaired hydroxylation (lack of oxygen) and can affect tumor cell behavior [142]. HIFs appear to be regulated appropriately within pVHL +/+ RCC cells, meaning that they can respond to hypoxia [124], as in the case of identified putative renal ALDH⁺ ACHN CSCs induced by hypoxic treatment [72]. However, it is unknown, what specifically initiates pVHL-wild-type ccRCC [124]. Mathieu et al. [167] showed that both 786-O pVHL –/– cells, cultured in normoxia, as well as pVHL +/+ cells, cultured in 2 % hypoxia, expressed similar levels of Oct4, Sox2 and Nanog markers. The question is, what happens within putative pVHL –/– pseudo-hypoxic renal CSCs when acute/chronic hypoxia starts to develop within a tumor? Might pseudo-hypoxic HIF overproduction increase

or has it already reached the limit and the number of induced *CSCs* remains at the same level?

Taken together, above-mentioned findings indicate that hypoxia rules immature cancer cell phenotype being an important aspect of the tumor microenvironment which, along with other *niche* components (such as growth factors), plays a fundamental role in conferring higher aggressiveness to tumor cells. It can be assumed that stem and non-stem cell-like populations exist in a dynamic equilibrium within a solid tumor. Therefore, hierarchical models of *CSCs* should be considered to serve as a microenvironment-stimulated interconversion between immature and mature tumor cell components [186]. Hypoxia alters expression level of hundreds of genes and, as a consequence, it is unlikely that a single mechanism can explain cell de-differentiation towards *CSC*-like phenotype induced by reduced oxygen tension. The combined effect of HIF-overactivation may ultimately impose attributes of stem cell identity on more differentiated transformed cells. However, it should be emphasized that this outcome would likely be a rare event – only these hypoxic cells which express a particular level of relevant stem cell factors would be expected to gain *CSC* characteristics [29]. Moreover, it is apparent from current literature that a fraction of cancer cells expressing specific surface marker(s) varies widely between tumors from less than 1 % to upwards of 25 %, but it remains uncertain whether these numbers reflect a true proportion of *CSCs* and/or all marker-positive cells possess *CSC*-like phenotype [126].

HIF-2 α as a RCC Oncogene

It is currently unknown why *VHL* gene inactivation is only linked to ccRCC, although both pVHL and HIFs are expressed in the majority of human cells [124]. It was observed, though, that the medulla of the mammalian kidney is hypoxic in normal physiological conditions [108]. Moreover, among various epithelia tested, renal epithelial cells seem to be particularly sensitive to mitogenic effects of HIF-responsive TGF- α [217, 218]. In addition, hypoxia causes the upregulation of cyclin D1 via HIF activation, stimulating cell proliferation of the renal epithelium, as opposed to other tissues [219–221]. Finally, some differences in proliferation rate between renal and other epithelial cell types have been observed. Intriguingly, epigenetic differences between cells within the kidney and other organs allow the renal epithelium to proliferate under reduced oxygen levels. Thus, it may be concluded that renal epithelial cells, proliferating in hypoxia, are more susceptible to oncogenic effects of the pVHL loss/HIF activation [124]. Other altered genes, which cooperate with the *VHL* gene loss of function to initiate tumor development, should also be identified [115]. Moreover, whether pVHL has any tumor-suppressor functions unrelated to its ability to inhibit HIFs needs to be understood, particularly in

view of such pVHL functions as the regulation of ECM formation and turnover, and the modulation of cell death [142].

While both HIF- α subunits show significant homology, most studies were focused on HIF-1 α due to its earlier discovery and more universal expression patterns within mammalian tissues than HIF-2 α , as HIF-2 α expression is restricted to particular cell types, including interstitial cells of the kidney [26, 29]. The role of HIF signaling during kidney development is unclear, but cell type- and stage-specific expression of HIF-1 α /2 α correlates with expression of critical angiogenic factors such as VEGF and CD105. Although HIF-1 α /2 α seem to activate hypoxia-responsive genes by similar means, they are non-redundant and regulate both overlapping and unique downstream target genes [138]. HIF-1 α /2 α were proven to be differently regulated in a number of tumors and seem to have a different impact on tumor behavior and patient outcome in neuroblastoma [222, 223], glioma/glioblastoma [154, 158] as well as breast [224] and non-small cell lung carcinoma [225, 226]. HIF-1 α was postulated to be involved in cell adaptation to acute hypoxia, whereas HIF-2 α to chronic hypoxia [222, 224]. Different expression patterns and roles of HIF-1 α /2 α in various tumors indicate the importance of their specificity for cancer survival and propagation [28]. With notable exceptions, HIF-1 α itself generally functions as an oncogene in a number of solid tumors, including breast, colon and brain cancer [107, 227], and its levels are informative negative prognostic factors for many malignancies, correlating with worse outcome [111, 228]. In pVHL $-/-$ ccRCC, in contrast, HIF-1 α appears to act as a tumor-suppressor [229]. In turn, HIF-2 α was supported as a tumor-suppressor in neuroblastoma, despite its promotion of angiogenesis [230]. However, a number of studies indicate that HIF-2 α may possibly function as an oncogene, but only in specific tumor types, in certain molecular contexts [152, 224, 225, 231, 232], also in RCC. Several findings on ccRCC show a particularly important role of HIF-2 α deregulation in pVHL-deficient pseudo-hypoxic renal carcinogenesis, proving that HIF-2 α , not HIF-1 α , is an oncogene, at least in the setting of this type of RCC:

1. HIF-1 α signaling pathways are activated early in development of VHL disease-associated pre-neoplastic kidney lesions, while HIF-2 α is detected in more advanced lesions. The apparent switch from HIF-1 α to HIF-2 α accumulation in more advanced lesions coincide with increased kidney dysplasia [233]. HIF-2 α expression is vital for ccRCC development in a mouse model [234].
2. ccRCC pVHL $-/-$ cell lines express either both HIF-1 α and HIF-2 α , or HIF-2 α alone, suggesting that there may be selection pressure to maintain HIF-2 α expression or lose HIF-1 α expression [121].
3. HIF-2 α variants lacking prolyl hydroxylation sites can override tumor suppression by pVHL in animal models, whereas analogous HIF-1 α mutants cannot, indicating

that HIF-2 α inhibition is necessary for pVHL-dependent tumor suppression [234–238].

4. HIF-2 α overexpression in ccRCC cell lines expressing functional pVHL results in enhanced xenograft tumor growth [234, 235, 238], in contrast to HIF-1 α which inhibits ccRCC growth [237, 238]. Moreover, HIF-2 α promotes (and HIF-1 α inhibits) pVHL-deficient ccRCC proliferation in vitro via c-Myc signaling [160] and its radiation resistance via phosphorylation inhibition of p53 [163].
5. The elimination of HIF-2 α through its siRNA-mediated downregulation is sufficient to suppress the in vivo tumor growth of pVHL-defective ccRCC cells [235, 239].
6. Despite the fact that both HIF- α isoforms target the same HREs during renal carcinogenesis, expression of genes involved in the glycolytic pathway is driven preferentially by HIF-1 α [240], whereas in pVHL-defective ccRCC cells, HIF-2 α preferentially promotes tumor growth and angiogenesis – it induces expression of cyclin D1, TGF- α and VEGF, which may be understood in the light of HIF-2 α being activated mainly during late ccRCC progression, in advanced lesions. However, in pVHL-competent RCC cells and non-RCC cells, cyclin D1, TGF- α and VEGF appear to be potentially responsive to both HIF- α isoforms [238].

C c i , The a e i c a i a d F i e Di e i

CSCs do not necessarily arise from altered normal stem cells, as they could also originate from normal differentiated cells that acquired self-renewal ability and became malignant [4, 35]. CSCs in some tumors may actually not be static and well defined, but rather display dynamic *stemness* properties depending on the microenvironmental context [186]. In line with this, putative TIC populations, identified in RCC, display diverse phenotypes/markers [47, 56–59, 61, 65–67, 70–72], as CSCs of malignant melanoma [23] as well as colorectal [16] and ovarian cancer [21]. Because CSC model in RCC is mainly based on functional approaches due to lack of generally applicable markers, it is important to optimize isolation and characterization methods of kidney-specific stem/progenitor cells to potentially rule them out as cells of TIC origin [3]. Currently, intensive attention is focused on the hypoxic microenvironment as a central mechanism governing CSCs [25–29] and related EMT/de-differentiation [25, 126, 190, 191, 195, 196] which, in turn, are being increasingly recognized as the goal to cure cancer. HIF signaling pathways have been studied in the last few years as extremely attractive targets of therapeutic intervention [117, 140, 241, 242]. Reduction of HIF activity in CSCs may promote their differentiation

[29]; on the other hand, disturbance of the *CSC niche* may also lead to loss of *stemness* characteristics [243] – both approaches might decrease tumor growth, improve its response to chemo- and radiotherapy, and diminish the ability to relapse. Despite the explosion of information on hypoxia in RCC progression, there are still major questions to be addressed in the field of the dependence of putative renal CSCs from their HIF signaling, especially oncogenic HIF-2 α .

In light of strong RCC resistance to chemo- and radiotherapy, and its high metastatic index, the identification of cells which are responsible for RCC development and maintenance, coupled with deep knowledge about their biomarkers, intra-cellular pathways and genetic abnormalities, may lead to efficient therapeutic strategies targeting this aggressive population by elimination and/or differentiation in various patient subtypes within different treatment responses and disease stages [3, 244]. A comprehensive molecular analysis of RCC [6, 245, 246] and pharmacogenomics of putative CSCs [247] are necessary for development of personalized treatment strategies. Epithelial differentiation of renal CD105⁺ TICs was tested – IL-15 was proposed as an interesting drug candidate [248]. Previous studies provide the rationale for this approach. First, IL-15 was shown in murine studies to be an autocrine survival factor for renal tubular epithelial cells. In addition, in vitro studies indicated that IL-15 upregulates expression of E-cadherin on human renal tubular epithelial cells and inhibits their EMT. Therefore, IL-15 is suggested to act as the sensor of normal tubular homeostasis. It can be speculated that a loss of intra-tumoral secretion of IL-15 by RCC might be a *stemness* protection mechanism of CD105⁺ cells [3]. After IL-15 treatment, renal CD105⁺ CSCs lacked stem cell markers, expressed epithelial markers and displayed the functional epithelial property of cell polarity. Epithelial differentiated renal CSCs were unable to self-renew, non-tumorigenic and drug-sensitive as well as acquired IL-15 secretion guaranteeing a permanent epithelial differentiation state through autocrine loops [248]. A phase I study of intravenous recombinant human IL-15 for the treatment of metastatic RCC was completed in February 2014 (NCT01021059). Another two phase I studies of subcutaneous IL-15 are ongoing (NCT01727076 and NCT02452268). Moreover, endoglin downregulation in epithelial ovarian cancer promoted apoptosis, induced significant DNA damage through modulation of numerous DNA repair genes, and improved platinum sensitivity both in vitro and in vivo, which implies that anti-CD105 therapy would allow dual treatment of both tumor angiogenesis and a subset of aggressive, chemoresistant CD105⁺ tumor cells [249]. A number of strategies to inhibit or downregulate (RNAi) another putative renal CSC marker, CXCR-4, have recently been proposed and are undergoing clinical trials [244]. In particular, downregulation of CXCR-4 using siRNA as well as its pharmacological inhibition by AMD3100 (Plerixafor) contributed to sphere formation blockade of CXCR-4⁺ RCC CSCs, and

increased their responsiveness towards anti-angiogenic agents Sunitinib, Sorafenib and Pazopanib [56]. Also, the DNAJB8 putative CSC marker of RCC was evaluated as an immunotherapeutic target in DNA vaccination experiments [57]. Furthermore, honokiol, a multifunctional anti-angiogenic and anti-tumor natural agent [250], inhibits proliferation, reverses EMT (increase in epithelial markers) and suppresses CSC properties of RCC cells both in vitro (invasiveness/migration, sphere formation, SP) and in vivo (tumorigenicity) [251]. Honokiol interferes with Ras/Raf/MEK/ERK tumor-promoting pathway [252]. In light of HIF-2 α dependence of pVHL-defective ccRCC progression, because SCD1 seems to maintain a positive feedback loop that upregulates HIF-2 α towards enhanced tumor progression, therapy targeting both SCD1 and HIF-2 α might be effective in the treatment of pVHL $-/-$ ccRCC [178]. Indeed, combinatorial application of SCD1 small molecule inhibitor, A939572, with mTOR inhibitor, Temsirolimus, synergistically attenuated in vitro and in vivo tumor growth in advanced/metastatic ccRCC patients [253]. In addition, in vitro studies on pVHL $-/-$ ccRCC cell lines indicate that Tempol, a stable nitroxide, has potential therapeutic activity against HIF-2 α [254].

The identification of the *VHL* gene and understanding of its molecular signaling pathways in renal carcinogenesis played a major role in development of novel targeted therapeutics against metastatic RCC. All these drugs share the ability to block HIF-VEGF-VEGFR and HIF-PDGF-PDGR axis that plays a significant role in tumor angiogenesis – their use may partially reverse the effect of pVHL loss of function, leading to tumor regression. Among currently licensed systemic targeted agents against advanced RCC, gradually introduced to clinical use since 2006, there are small-molecule multiple RTK inhibitors such as Sunitinib (*SUTENT*, Pfizer Inc.), Sorafenib (*Nexavar*, Bayer HealthCare/Onyx Pharmaceuticals), Pazopanib (*Votrient*, GlaxoSmithKline) and Axitinib (*Inlyta*, Pfizer); the neutralizing anti-VEGF humanized monoclonal antibody, Bevacizumab (*Avastin*, Genentech), given in combination with IFN- α ; and inhibitors of serine-threonine mTOR kinase complexes (mTORC1 and mTORC2), Temsirolimus (*Torisel*, Pfizer) and Everolimus (*Afinitor*, Novartis Pharmaceuticals) [255, 256]. mTOR is a highly conserved kinase implicated in RCC development, as it is involved in transcriptional regulation of HIF-1 α [142] and HIF-2 α [179]. Novel targeted therapeutics, used in combination or sequentially, significantly improved outcomes of patients with metastatic RCC, showing higher objective response rate and higher median progression-free survival compared to reference treatment. Results from ongoing/planned clinical trials are expected to help to shape effective RCC future therapeutic possibilities [255, 256]. Despite therapeutic progress, complete and durable responses are rarely noted, necessitating chronic therapy for the majority of RCC patients which is often associated with significant toxicity. In addition,

the response to treatment with a specific targeted drug differs between patients, suggesting specific molecular mechanisms promoting individual susceptibility to each agent [255]. Patients who primarily respond to anti-angiogenic targeted treatment often develop acquired (adaptive, evasive) resistance [255, 257–260]. The initial inhibition of tumor growth and prolongation of progression-free survival due to anti-angiogenic therapy are associated with relapse and more invasive metastatic disease [212]. Secondary intra-tumor acute hypoxic condition following anti-angiogenic RCC therapy-associated disruption in vasculature was proposed to promote alternative strategies to support angiogenesis (*angiogenic switch*) such as selection of tumor cell clones independent of VEGF due to multiple molecular and/or cellular mechanisms [255, 257]. Moreover, regarding one of identified presumable ALDH⁺CSC-like populations of RCC, anti-angiogenic Sorafenib treatment induced a 2–3 fold increase in a number of ALDH⁺ ACHN cells as compared with normal conditions [72]. Furthermore, a study of tumorigenic CD133/CXCR-4-co-expressing cells, contradicting a general conviction that CD133 is not a marker of renal CSCs, showed a promoting effect of Sunitinib-induced hypoxia in tumor perinecrotic areas on the number of these cells, thus, Sunitinib was able to generate resistance to its own therapeutic effect [86]. Indeed, high CXCR-4 expression correlates with poor response to anti-angiogenic treatment (including Sunitinib) in metastatic RCC [56, 261]. In vitro studies revealed that CSC increase in breast carcinoma xenografts due to anti-angiogenic treatment (Sunitinib and Bevacizumab) followed by hypoxic conditions is primarily mediated by HIF-1 α (EMT induction) [262]. In line with this, xenograft studies showed that hypoxia-activated EMT may be responsible for RCC resistance to Sunitinib [198]. Finally, induction of the VM phenomenon, possibly by the switch from normal to embryonic-like tumor vasculogenesis dependent from endothelial differentiation of CSCs [211, 212] which was shown in RCC [47, 59] as well as in hypoxic conditions in breast carcinoma [53] and leukemia [263], may also be responsible for tumor escape from conventional anti-angiogenic therapies. However, VEGFR inhibition by Sunitinib, but not VEGF blockade using Bevacizumab, impaired hypoxia-induced endothelial differentiation of renal CD105⁺CSCs in vitro, suggesting a VEGF-independent mechanism [264]. Considering a strict dependence of RCC on angiogenesis for tumor promotion, putative RCC CSCs may be speculated to display distinct pro-angiogenic properties [3], especially in light of pVHL inactivation.

In view of development of secondary hypoxia limiting the effectiveness of current therapy, anti-angiogenic agents should perhaps be combined with renal CSC-targeting drugs. In addition, an innovative therapeutic perspective might be the use of hyperoxia/hyperbaric oxygen to decrease the number of CSCs in resistant metastases (e.g., due to restoration of more

differentiated phenotype), resensitizing them [265]. Moreover, a highly challenging issue is counteracting hypoxia-related limitations of anti-angiogenic drugs by tumor vessel normalization (restoration of healthy vasculature) using ITPP [266] and a soluble form of VEGFR-2 [267] in order to inhibit CSC selection and improve treatment efficiency. Another problematic phenomenon for RCC therapy may be EndoMT – the de-differentiation process of endothelial cells to invasive CAFs which is induced by TGF- β [268]. Within the tumor microenvironment, CAFs are supposed to cooperate to tumor aggressiveness by the interaction with and modification of CSCs [190]. Finally, in the context of tumor hypoxia, the wide use of rhEPO to treat anaemia in cancer patients, especially ccRCC, is still being discussed because of HIF-induced EPO and EPOR overexpression. On the one hand, binding of exogenous rhEPO with EPOR might prevent or stabilize tumor progression by decreasing hypoxia through increasing oxygenation (erythrocytosis). The alternative argument indicates the possibility of rhEPO/EPOR-mediated initiation of autocrine/paracrine pathways promoting progression [197].

A c k n o w l e d g e m e n t s This work was supported by National Science Center, grant No UMO-2011/01/B/NZ5/02822.

C o n f l i c t o f i n t e r e s t The authors declare no potential conflicts.

O p e n A c c e s s This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

- Siegel, R. L., Miller, K. D., & Jemal, A. (2015). Cancer Statistics, 2015. *CA: A Cancer Journal for Clinicians*, 65(1), 5–29.
- Koul, H., Huh, J. S., Rove, K. O., et al. (2011). Molecular aspects of renal cell carcinoma: a review. *American Journal of Cancer Research*, 1(2), 240–254.
- Bussolati, B., Dekel, B., Azzarone, B., & Camussi, G. (2013). Human renal cancer stem cells. *Cancer Letters*, 338(1), 141–146.
- Axelsson, H., & Johansson, M. E. (2013). Renal stem cells and their implications for kidney cancer. *Seminars in Cancer Biology*, 23(1), 56–61.
- Novick, A. C. (2007). Kidney cancer: past, present, and future. *Urologic Oncology*, 25(3), 188–195.
- Gerlinger, M., Rowan, A. J., Horswell, S., et al. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *The New England Journal of Medicine*, 366(10), 883–892.
- Marusyk, A., & Polyak, K. (2010). Tumor heterogeneity: causes and consequences. *Biochimica et Biophysica Acta*, 1805(1), 105–117.
- Visvader, J. E., & Lindeman, G. J. (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. *Nature Reviews Cancer*, 8(10), 755–768.
- Visvader, J. E., & Lindeman, G. J. (2012). Cancer stem cells: current status and evolving complexities. *Cell Stem Cell*, 10(6), 717–728.
- Clevers, H. (2011). The cancer stem cell: promises, promises and challenges. *Nature Medicine*, 17(3), 313–319.
- Pardoll, R., Clarke, M. F., & Morrison, S. J. (2003). Applying the principles of stem-cell biology to cancer. *Nature Reviews Cancer*, 3(12), 895–902.
- Greaves, M. (2007). Darwinian medicine: a case for cancer. *Nature Reviews Cancer*, 7(3), 213–221.
- Michor, F., & Polyak, K. (2010). The origins and implications of intratumor heterogeneity. *Cancer Prevention Research (Philadelphia)*, 3(11), 1361–1364.
- Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, 100(7), 3983–3988.
- Singh, S. K., Hawkins, C., Clarke, I. D., et al. (2004). Identification of human brain tumour initiating cells. *Nature*, 432(7015), 396–401.
- Vaiopoulos, A. G., Kostakis, I. D., Koutsilieris, M., & Papavassiliou, A. G. (2012). Colorectal cancer stem cells. *Stem Cells*, 30(3), 363–371.
- Fitzgerald, T. L., & McCubrey, J. A. (2014). Pancreatic cancer stem cells: association with cell surface markers, prognosis, resistance, metastasis and treatment. *Advances in Biological Regulation*, 56, 45–50.
- Yang, Z. F., Ho, D. W., Ng, M. N., et al. (2008). Significance of CD90+ cancer stem cells in human liver cancer. *Cancer Cell*, 13(2), 153–166.
- Bertolini, G., Roz, L., Perego, P., et al. (2009). Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. *Proceedings of the National Academy of Sciences of the United States of America*, 106(38), 16281–16286.
- Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J., & Maitland, N. J. (2005). Prospective identification of tumorigenic prostate cancer stem cells. *Cancer Research*, 65(23), 10946–10951.
- Foster, R., Buckanovich, R. J., & Rueda, B. R. (2013). Ovarian cancer stem cells: working towards the root of stemness. *Cancer Letters*, 338(1), 147–157.
- Rutella, S., Bonanno, G., Procoli, A., et al. (2009). Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. *Clinical Cancer Research*, 15(13), 4299–4311.
- Shakhova, O., & Sommer, L. (2013). Testing the cancer stem cell hypothesis in melanoma: the clinics will tell. *Cancer Letters*, 338(1), 74–81.
- Gedye, C., Sirskyj, D., Lobo, N. C., et al. (2014). Essential experimental steps and estimates of renal carcinoma initiating cells. *Journal of Clinical Oncology*, 32:5 s, suppl; abstr 11127.
- Mimeault, M., & Batra, S. K. (2013). Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. *Journal of Cellular and Molecular Medicine*, 17(1), 30–54.
- Li, Z., & Rich, J. N. (2010). Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. *Current Topics in Microbiology and Immunology*, 345, 21–30.
- Mazumdar, J., Dondeti, V., & Simon, M. C. (2009). Hypoxia-inducible factors in stem cells and cancer. *Journal of Cellular and Molecular Medicine*, 13(11–12), 4319–4328.
- Heddleston, J. M., Li, Z., Lathia, J. D., Bao, S., Hjelmeland, A. B., & Rich, J. N. (2010). Hypoxia inducible factors in cancer stem cells. *British Journal of Cancer*, 102(5), 789–795.
- Keith, B., & Simon, M. C. (2007). Hypoxia-inducible factors, stem cells, and cancer. *Cell*, 129(3), 465–472.
- Grosse-Gehling, P., Fargeas, C. A., Dittfeld, C., et al. (2013). CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. *Journal of Pathology*, 229(3), 355–378.

31. Angelotti, M. L., Lazzeri, E., Lasagni, L., & Romagnani, P. (2010). Only anti-CD133 antibodies recognizing the CD133/1 or the CD133/2 epitopes can identify human renal progenitors. *Kidney International*, 78(6), 620–621. author reply 621.
32. Kemper, K., Sprick, M. R., de Bree, M., et al. (2010). The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. *Cancer Research*, 70(2), 719–729.
33. Bruno, S., Bussolati, B., Grange, C., et al. (2006). CD133+ renal progenitor cells contribute to tumor angiogenesis. *American Journal of Pathology*, 169(6), 2223–2235.
34. Caplan, A. I., & Bruder, S. P. (2001). Mesenchymal stem cells: building blocks for molecular medicine in the 21st century. *Trends in Molecular Medicine*, 7(6), 259–264.
35. Bussolati, B., Brossa, A., & Camussi, G. (2011). Resident stem cells and renal carcinoma. *International Journal of Nephrology*, 2011, 286985.
36. Bussolati, B., Bruno, S., Grange, C., et al. (2005). Isolation of renal progenitor cells from adult human kidney. *American Journal of Pathology*, 166(2), 545–555.
37. Lindgren, D., Boström, A. K., Nilsson, K., et al. (2011). Isolation and characterization of progenitor-like cells from human renal proximal tubules. *American Journal of Pathology*, 178(2), 828–837.
38. Sallustio, F., De Benedictis, L., Castellano, G., et al. (2010). TLR2 plays a role in the activation of human resident renal stem/progenitor cells. *FASEB Journal*, 24(2), 514–525.
39. Ronconi, E., Sagrinati, C., Angelotti, M. L., et al. (2009). Regeneration of glomerular podocytes by human renal progenitors. *Journal of the American Society of Nephrology*, 20(2), 322–332.
40. Sagrinati, C., Netti, G. S., Mazzinghi, B., et al. (2006). Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys. *Journal of the American Society of Nephrology*, 17(9), 2443–2456.
41. Bussolati, B., Moggio, A., Collino, F., et al. (2012). Hypoxia modulates the undifferentiated phenotype of human renal inner medullary CD133+ progenitors through Oct4/miR-145 balance. *American Journal of Physiology. Renal Physiology*, 302(1), F116–128.
42. Ivanova, L., Hiatt, M. J., Yoder, M. C., Tarantal, A. F., & Matsell, D. G. (2010). Ontogeny of CD24 in the human kidney. *Kidney International*, 77(12), 1123–1131.
43. Lazzeri, E., Crescioli, C., Ronconi, E., et al. (2007). Regenerative potential of embryonic renal multipotent progenitors in acute renal failure. *Journal of the American Society of Nephrology*, 18(12), 3128–3138.
44. Duff, S. E., Li, C., Garland, J. M., & Kumar, S. (2003). CD105 is important for angiogenesis: evidence and potential applications. *FASEB Journal*, 17(9), 984–992.
45. Dallas, N. A., Samuel, S., Xia, L., et al. (2008). Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. *Clinical Cancer Research*, 14(7), 1931–1937.
46. Li, C., Issa, R., Kumar, P., et al. (2003). CD105 prevents apoptosis in hypoxic endothelial cells. *Journal of Cell Science*, 116(Pt 13), 2677–2685.
47. Bussolati, B., Bruno, S., Grange, C., Ferrando, U., & Camussi, G. (2008). Identification of a tumor-initiating stem cell population in human renal carcinomas. *FASEB Journal*, 22(10), 3696–3705.
48. Hu, D., Wang, X., Mao, Y., & Zhou, L. (2012). Identification of CD105 (endoglin)-positive stem-like cells in rhabdoid meningioma. *Journal of Neuro-Oncology*, 106(3), 505–517.
49. Gibbs, C. P., Kukekov, V. G., Reith, J. D., et al. (2005). Stem-like cells in bone sarcomas: implications for tumorigenesis. *Neoplasia*, 7(11), 967–976.
50. Ricci-Vitiani, L., Pallini, R., Biffoni, M., et al. (2010). Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. *Nature*, 468(7325), 824–828.
51. Xiong, Y. Q., Sun, H. C., Zhang, W., et al. (2009). Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. *Clinical Cancer Research*, 15(15), 4838–4846.
52. Alvero, A. B., Fu, H. H., Holmberg, J., et al. (2009). Stem-like ovarian cancer cells can serve as tumor vascular progenitors. *Stem Cells*, 27(10), 2405–2413.
53. Bussolati, B., Grange, C., Sapino, A., & Camussi, G. (2009). Endothelial cell differentiation of human breast tumour stem/progenitor cells. *Journal of Cellular and Molecular Medicine*, 13(8), 309–319.
54. Grange, C., Tapparo, M., Collino, F., et al. (2011). Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. *Cancer Research*, 71(15), 5346–5356.
55. Lindoso, R. S., Collino, F., & Camussi, G. (2015). Extracellular vesicles derived from renal cancer stem cells induce a pro-tumorigenic phenotype in mesenchymal stromal cells. *Oncotarget*, 6(10), 7959–7969.
56. Gassenmaier, M., Chen, D., Buchner, A., et al. (2013). CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis. *Stem Cells*, 31(8), 1467–1476.
57. Nishizawa, S., Hirohashi, Y., Torigoe, T., et al. (2012). HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells. *Cancer Research*, 72(11), 2844–2854.
58. Zhong, Y., Guan, K., Guo, S., et al. (2010). Spheres derived from the human SK-RC-42 renal cell carcinoma cell line are enriched in cancer stem cells. *Cancer Letters*, 299(2), 150–160.
59. Lichner, Z., Saleh, C., Subramaniam, V., Seivwright, A., Prud'homme, G. J., & Yousef, G. M. (2015). miR-17 inhibition enhances the formation of kidney cancer spheres with stem cell/tumor initiating cell properties. *Oncotarget*, 6(8), 5567–5581.
60. Wu, C., & Alman, B. A. (2008). Side population cells in human cancers. *Cancer Letters*, 268(1), 1–9.
61. Addla, S. K., Brown, M. D., Hart, C. A., Ramani, V. A., & Clarke, N. W. (2008). Characterization of the Hoechst 33342 side population from normal and malignant human renal epithelial cells. *American Journal of Physiology. Renal Physiology*, 295(3), F680–687.
62. Goodell, M. A., Brose, K., Paradis, G., Conner, A. S., & Mulligan, R. C. (1996). Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. *The Journal of Experimental Medicine*, 183(4), 1797–1806.
63. Broadley, K. W., Hunn, M. K., Farrand, K. J., et al. (2011). Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme. *Stem Cells*, 29(3), 452–461.
64. Golebiewska, A., Brons, N. H., Bjerkvig, R., & Niclou, S. P. (2011). Critical appraisal of the side population assay in stem cell and cancer stem cell research. *Cell Stem Cell*, 8(2), 136–147.
65. Oates, J. E., Grey, B. R., Addla, S. K., et al. (2009). Hoechst 33342 side population identification is a conserved and unified mechanism in urological cancers. *Stem Cells and Development*, 18(10), 1515–1522.
66. Huang, B., Huang, Y. J., Yao, Z. J., et al. (2013). Cancer stem cell-like side population cells in clear cell renal cell carcinoma cell line 769P. *PLoS ONE*, 8(7), e68293.
67. Lu, J., Cui, Y., Zhu, J., He, J., Zhou, G., & Yue, Z. (2013). Biological characteristics of Rh123 stem-like cells in a side population of 786-O renal carcinoma cells. *Oncology Letters*, 5(6), 1903–1908.
68. Hughes, C., Liew, M., Sachdeva, A., et al. (2010). SR-FTIR spectroscopy of renal epithelial carcinoma side population cells displaying stem cell-like characteristics. *Analyst*, 135(12), 3133–3141.
69. Marcatò, P., Dean, C. A., Giacomantonio, C. A., & Lee, P. W. (2011). Aldehyde dehydrogenase: its role as a cancer stem cell

- marker comes down to the specific isoform. *Cell Cycle*, 10(9), 1378–1384.
70. Debeb, B. G., Zhang, X., Krishnamurthy, S., et al. (2010). Characterizing cancer cells with cancer stem cell-like features in 293 T human embryonic kidney cells. *Molecular Cancer*, 9, 180.
 71. Wang, L., Park, P., Zhang, H., La Marca, F., & Lin, C. Y. (2011). Characterization of renal tumor-initiating cells in human renal carcinoma cell lines. *Cancer Research*, 71, 8 suppl; abstr 293.
 72. Ueda, K., Ogasawara, S., Akiba, J., et al. (2013). Aldehyde dehydrogenase 1 identifies cells with cancer stem cell-like properties in a human renal cell carcinoma cell line. *PLoS ONE*, 8(10), e75463.
 73. Shukrun, R., Pode Shakked, N., & Dekel, B. (2014). Targeted therapy aimed at cancer stem cells: Wilms' tumor as an example. *Pediatric Nephrology*, 29(5), 815–823.
 74. Benigni, A., Morigi, M., & Remuzzi, G. (2010). Kidney regeneration. *Lancet*, 375(9722), 1310–1317.
 75. Gupta, S., & Rosenberg, M. E. (2008). Do stem cells exist in the adult kidney? *American Journal of Nephrology*, 28(4), 607–613.
 76. Bruno, S., Bussolati, B., Grange, C., et al. (2009). Isolation and characterization of resident mesenchymal stem cells in human glomeruli. *Stem Cells and Development*, 18(6), 867–880.
 77. Metsuyanin, S., Harari-Steinberg, O., Buzhor, E., et al. (2009). Expression of stem cell markers in the human fetal kidney. *PLoS ONE*, 4(8), e6709.
 78. Cantley, L. G. (2005). Adult stem cells in the repair of the injured renal tubule. *Nature Clinical Practice Nephrology*, 1(1), 22–32.
 79. da Silva Meirelles, L., Chagastelles, P. C., & Nardi, N. B. (2006). Mesenchymal stem cells reside in virtually all post-natal organs and tissues. *Journal of Cell Science*, 119(Pt 11), 2204–2213.
 80. Gupta, S., Verfaillie, C., Chmielewski, D., et al. (2006). Isolation and characterization of kidney-derived stem cells. *Journal of the American Society of Nephrology*, 17(11), 3028–3040.
 81. Park, H. C., Yasuda, K., Kuo, M. C., et al. (2010). Renal capsule as a stem cell niche. *American Journal of Physiology. Renal Physiology*, 298(5), F1254–F1262.
 82. D'Alterio, C., Cindolo, L., Portella, L., et al. (2010). Differential role of CD133 and CXCR4 in renal cell carcinoma. *Cell Cycle*, 9(22), 4492–4500.
 83. Kim, K., Ihm, H., Ro, J. Y., & Cho, Y. M. (2011). High-level expression of stem cell marker CD133 in clear cell renal cell carcinoma with favorable prognosis. *Oncology Letters*, 2(6), 1095–1100.
 84. Canis, M., Lechner, A., Mack, B., et al. (2013). CD133 induces tumour-initiating properties in HEK293 cells. *Tumour Biology*, 34(1), 437–443.
 85. Galleggiante, V., Rutigliano, M., Sallustio, F., et al. (2014). CTR2 identifies a population of cancer cells with stem cell-like features in patients with clear cell renal cell carcinoma. *Journal of Urology*, 192(6), 1831–1841.
 86. Varna, M., Gapihan, G., Feugeas, J. P., et al. (2015). Stem cells increase in numbers in perinecrotic areas in human renal cancer. *Clinical Cancer Research*, 21(4), 916–924.
 87. Vogetseder, A., Picard, N., Gaspert, A., Walch, M., Kaissling, B., & Le Hir, M. (2008). Proliferation capacity of the renal proximal tubule involves the bulk of differentiated epithelial cells. *American Journal of Physiology. Cell Physiology*, 294(1), C22–28.
 88. Vogetseder, A., Karadeniz, A., Kaissling, B., & Le Hir, M. (2005). Tubular cell proliferation in the healthy rat kidney. *Histochemistry and Cell Biology*, 124(2), 97–104.
 89. Vogetseder, A., Palan, T., Bacic, D., Kaissling, B., & Le Hir, M. (2007). Proximal tubular epithelial cells are generated by division of differentiated cells in the healthy kidney. *American Journal of Physiology. Cell Physiology*, 292(2), C807–813.
 90. Humphreys, B. D., Valerius, M. T., Kobayashi, A., et al. (2008). Intrinsic epithelial cells repair the kidney after injury. *Cell Stem Cell*, 2(3), 284–291.
 91. Humphreys, B. D., Czerniak, S., DiRocco, D. P., Hasnain, W., Cheema, R., & Bonventre, J. V. (2011). Repair of injured proximal tubule does not involve specialized progenitors. *Proceedings of the National Academy of Sciences of the United States of America*, 108(22), 9226–9231.
 92. Bonventre, J. V. (2003). Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. *Journal of the American Society of Nephrology*, 14(suppl 1), S55–61.
 93. Witzgall, R., Brown, D., Schwarz, C., & Bonventre, J. V. (1994). Localization of proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin in the postischemic kidney. Evidence for a heterogeneous genetic response among nephron segments, and a large pool of mitotically active and dedifferentiated cells. *The Journal of Clinical Investigation*, 93(5), 2175–2188.
 94. Mani, S. A., Guo, W., Liao, M. J., et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell*, 133(4), 704–715.
 95. Imgrund, M., Gröne, E., Gröne, H. J., et al. (1999). Re-expression of the developmental gene Pax-2 during experimental acute tubular necrosis in mice 1. *Kidney International*, 56(4), 1423–1431.
 96. Humphreys, B. D., & Bonventre, J. V. (2008). Mesenchymal stem cells in acute kidney injury. *Annual Review of Medicine*, 59, 311–325.
 97. Galiè, M., Konstantinidou, G., Peroni, D., et al. (2008). Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice. *Oncogene*, 27(18), 2542–2551.
 98. Aractingi, S., Kanitakis, J., Euvrard, S., et al. (2005). Skin carcinoma arising from donor cells in a kidney transplant recipient. *Cancer Research*, 65(5), 1755–1760.
 99. Barozzi, P., Luppi, M., Facchetti, F., et al. (2003). Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. *Nature Medicine*, 9(5), 554–561.
 100. Boix, R., Sanz, C., Mora, M., et al. (2009). Primary renal cell carcinoma in a transplanted kidney: genetic evidence of recipient origin. *Transplantation*, 87(7), 1057–1061.
 101. Houghton, J., Stoicov, C., Nomura, S., et al. (2004). Gastric cancer originating from bone marrow-derived cells. *Science*, 306(5701), 1568–1571.
 102. Gedye, C., Sirskyj, D., Lobo, N. C., et al. (2013). VHL-mutant renal cell carcinomas contain cancer cells with mesenchymal phenotypes. *Journal of Clinical Oncology*, 31, suppl; abstr 4568.
 103. Li, H., Fan, X., Kovi, R. C., et al. (2007). Spontaneous expression of embryonic factors and p53 point mutations in aged mesenchymal stem cells: a model of age-related tumorigenesis in mice. *Cancer Research*, 67(22), 10889–10898.
 104. Kurose, K., Gilley, K., Matsumoto, S., Watson, P. H., Zhou, X. P., & Eng, C. (2002). Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. *Nature Genetics*, 32(3), 355–357.
 105. Hu, M., Yao, J., Cai, L., et al. (2005). Distinct epigenetic changes in the stromal cells of breast cancers. *Nature Genetics*, 37(8), 899–905.
 106. Pelham, R. J., Rodgers, L., Hall, I., et al. (2006). Identification of alterations in DNA copy number in host stromal cells during tumor progression. *Proceedings of the National Academy of Sciences of the United States of America*, 103(52), 19848–19853.
 107. Bertout, J. A., Patel, S. A., & Simon, M. C. (2008). The impact of O₂ availability on human cancer. *Nature Reviews Cancer*, 8(12), 967–975.
 108. Brezis, M., & Rosen, S. (1995). Hypoxia of the renal medulla—its implications for disease. *The New England Journal of Medicine*, 332(10), 647–655.
 109. Höckel, M., & Vaupel, P. (2001). Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. *Journal of the National Cancer Institute*, 93(4), 266–276.

110. Vaupel, P., & Harrison, L. (2004). Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. *The Oncologist*, 9(suppl 5), 4–9.
111. Vaupel, P., & Mayer, A. (2007). Hypoxia in cancer: significance and impact on clinical outcome. *Cancer and Metastasis Reviews*, 26(2), 225–239.
112. Harris, A. L. (2002). Hypoxia—a key regulatory factor in tumour growth. *Nature Reviews Cancer*, 2(1), 38–47.
113. Jaakkola, P., Mole, D. R., Tian, Y. M., et al. (2001). Targeting of HIF- α to the von Hippel-Lindau ubiquitylation complex by O₂-regulated prolyl hydroxylation. *Science*, 292(5516), 468–472.
114. Kaelin, W. G., Jr. (2004). The Von Hippel-Lindau tumor suppressor gene and kidney cancer. *Clinical Cancer Research*, 10(18 Pt 2), 6290S–6295S.
115. Kim, W. Y., & Kaelin, W. G. (2004). Role of VHL gene mutation in human cancer. *Journal of Clinical Oncology*, 22(24), 4991–5004.
116. Kim, W. Y., & Kaelin, W. G., Jr. (2006). Molecular pathways in renal cell carcinoma—rationale for targeted treatment. *Seminars in Oncology*, 33(5), 588–595.
117. Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. *Nature Reviews Cancer*, 3(10), 721–732.
118. Latif, F., Tory, K., Gnarr, J., et al. (1993). Identification of the von Hippel-Lindau disease tumor suppressor gene. *Science*, 260(5112), 1317–1320.
119. Kaelin, W. G., Jr., & Maher, E. R. (1998). The VHL tumour-suppressor gene paradigm. *Trends in Genetics*, 14(10), 423–426.
120. Ivan, M., Kondo, K., Yang, H., et al. (2001). HIF α targeted for VHL-mediated destruction by proline hydroxylation: implications for O₂ sensing. *Science*, 292(5516), 464–468.
121. Maxwell, P. H., Wiesener, M. S., Chang, G. W., et al. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. *Nature*, 399(6733), 271–275.
122. Richards, F. M. (2001). Molecular pathology of von Hippel Lindau disease and the VHL tumour suppressor gene. *Expert Reviews in Molecular Medicine*, 2001, 1–27.
123. Carroll, V. A., & Ashcroft, M. (2006). Role of hypoxia-inducible factor (HIF)-1 α versus HIF-2 α in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. *Cancer Research*, 66(12), 6264–6270.
124. Kaelin, W. G., Jr. (2007). The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. *Clinical Cancer Research*, 13(2 Pt 2), 680s–684s.
125. Pouyssegur, J., Dayan, F., & Mazure, N. M. (2006). Hypoxia signalling in cancer and approaches to enforce tumour regression. *Nature*, 441(7092), 437–443.
126. Hill, R. P., Marie-Egyptienne, D. T., & Hedley, D. W. (2009). Cancer stem cells, hypoxia and metastasis. *Seminars in Radiation Oncology*, 19(2), 106–111.
127. Makino, Y., Cao, R., Svensson, K., et al. (2001). Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. *Nature*, 414(6863), 550–554.
128. Seizinger, B. R., Rouleau, G. A., Ozelius, L. J., et al. (1988). Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. *Nature*, 332(6161), 268–269.
129. Knudson, A. G., Jr. (1971). Mutation and cancer: statistical study of retinoblastoma. *Proceedings of the National Academy of Sciences of the United States of America*, 68(4), 820–823.
130. Iliopoulos, O., Kibel, A., Gray, S., & Kaelin, W. G., Jr. (1995). Tumour suppression by the human von Hippel-Lindau gene product. *Nature Medicine*, 1(8), 822–826.
131. Foster, K., Prowse, A., van den Berg, A., et al. (1994). Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. *Human Molecular Genetics*, 3(12), 2169–2173.
132. Brauch, H., Weirich, G., Brieger, J., et al. (2000). VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. *Cancer Research*, 60(7), 1942–1948.
133. Shuin, T., Kondo, K., Torigoe, S., et al. (1994). Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. *Cancer Research*, 54(11), 2852–2855.
134. Gnarr, J. R., Lerman, M. I., Zbar, B., & Linehan, W. M. (1995). Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. *Seminars in Oncology*, 22(1), 3–8.
135. Banks, R. E., Tirukonda, P., Taylor, C., et al. (2006). Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. *Cancer Research*, 66(4), 2000–2011.
136. Herman, J. G., Latif, F., Weng, Y., et al. (1994). Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, 91(21), 9700–9704.
137. Fiorentini, G., Aliberti, C., Benea, G., et al. (2009). Effects of Molecularly Targeting Hypoxia in Oncology. In G. Baronzio, G. Fiorentini, & C. R. Cogle (Eds.), *Cancer Microenvironment and Therapeutic Implications* (pp. 117–135). Netherlands: Springer.
138. Pietras, A., Johnsson, A. S., & Pahlman, S. (2010). The HIF-2 α -driven pseudo-hypoxic phenotype in tumor aggressiveness, differentiation, and vascularization. *Current Topics in Microbiology and Immunology*, 345, 1–20.
139. Gordan, J. D., & Simon, M. C. (2007). Hypoxia-inducible factors: central regulators of the tumor phenotype. *Current Opinion in Genetics & Development*, 17(1), 71–77.
140. Wilson, W. R., & Hay, M. P. (2011). Targeting hypoxia in cancer therapy. *Nature Reviews Cancer*, 11(6), 393–410.
141. Liao, D., & Johnson, R. S. (2007). Hypoxia: a key regulator of angiogenesis in cancer. *Cancer and Metastasis Reviews*, 26(2), 281–290.
142. Kaelin, W. G., Jr. (2008). The von Hippel-Lindau tumour suppressor protein: O₂ sensing and cancer. *Nature Reviews Cancer*, 8(11), 865–873.
143. Barnhart, B. C., & Simon, M. C. (2007). Metastasis and stem cell pathways. *Cancer and Metastasis Reviews*, 26(2), 261–271.
144. Ezashi, T., Das, P., & Roberts, R. M. (2005). Low O₂ tensions and the prevention of differentiation of hES cells. *Proceedings of the National Academy of Sciences of the United States of America*, 102(13), 4783–4788.
145. Carreau, A., El Hafny-Rahbi, B., Matejuk, A., Grillon, C., & Kieda, C. (2011). Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. *Journal of Cellular and Molecular Medicine*, 15(6), 1239–1253.
146. Grayson, W. L., Zhao, F., Izadpanah, R., Bunnell, B., & Ma, T. (2006). Effects of hypoxia on human mesenchymal stem cell expansion and plasticity in 3D constructs. *Journal of Cellular Physiology*, 207(2), 331–339.
147. Morrison, S. J., Csete, M., Groves, A. K., Melega, W., Wold, B., & Anderson, D. J. (2000). Culture in reduced levels of oxygen promotes clonogenic sympathetic differentiation by isolated neural crest stem cells. *The Journal of Neuroscience*, 20(19), 7370–7376.
148. Mohyeldin, A., Garzón-Muvdi, T., & Quiñones-Hinojosa, A. (2010). Oxygen in stem cell biology: a critical component of the stem cell niche. *Cell Stem Cell*, 7(2), 150–161.
149. Mao, Q., Zhang, Y., Fu, X., et al. (2013). A tumor hypoxic niche protects human colon cancer stem cells from chemotherapy. *Journal of Cancer Research and Clinical Oncology*, 139(2), 211–222.

150. Das, B., Tsuchida, R., Malkin, D., Koren, G., Baruchel, S., & Yeger, H. (2008). Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. *Stem Cells*, 26(7), 1818–1830.
151. Seidel, S., Garvalov, B. K., Wirta, V., et al. (2010). A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. *Brain*, 133(Pt 4), 983–995.
152. Pietras, A., Gisselsson, D., Ora, I., et al. (2008). High levels of HIF-2alpha highlight an immature neural crest-like neuroblastoma cell cohort located in a perivascular niche. *Journal of Pathology*, 214(4), 482–488.
153. Pietras, A., Hansford, L. M., Johnsson, A. S., et al. (2009). Hif-2alpha maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells. *Proceedings of the National Academy of Sciences of the United States of America*, 106(39), 16805–16810.
154. Li, Z., Bao, S., Wu, Q., et al. (2009). Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. *Cancer Cell*, 15(6), 501–513.
155. McCord, A. M., Jamal, M., Shankavaram, U. T., Lang, F. F., Camphausen, K., & Tofilon, P. J. (2009). Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. *Molecular Cancer Research*, 7(4), 489–497.
156. Soeda, A., Park, M., Lee, D., et al. (2009). Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. *Oncogene*, 28(45), 3949–3959.
157. Platet, N., Liu, S. Y., Atifi, M. E., et al. (2007). Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. *Cancer Letters*, 258(2), 286–290.
158. Heddleston, J. M., Li, Z., McLendon, R. E., Hjelmeland, A. B., & Rich, J. N. (2009). The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. *Cell Cycle*, 8(20), 3274–3284.
159. Dang, C. V., Kim, J. W., Gao, P., & Yuste, J. (2008). The interplay between MYC and HIF in cancer. *Nature Reviews Cancer*, 8(1), 51–56.
160. Gordan, J. D., Bertout, J. A., Hu, C. J., Diehl, J. A., & Simon, M. C. (2007). HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. *Cancer Cell*, 11(4), 335–347.
161. Koshiji, M., Kageyama, Y., Pete, E. A., Horikawa, I., Barrett, J. C., & Huang, L. E. (2004). HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. *EMBO Journal*, 23(9), 1949–1956.
162. Gordan, J. D., Lal, P., Dondeti, V. R., et al. (2008). HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. *Cancer Cell*, 14(6), 435–446.
163. Bertout, J. A., Majmundar, A. J., Gordan, J. D., et al. (2009). HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. *Proceedings of the National Academy of Sciences of the United States of America*, 106(34), 14391–14396.
164. Covelto, K. L., Kehrer, J., Yu, H., et al. (2006). HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. *Genes and Development*, 20(5), 557–570.
165. Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*, 126(4), 663–676.
166. Yoshida, Y., Takahashi, K., Okita, K., Ichisaka, T., & Yamanaka, S. (2009). Hypoxia enhances the generation of induced pluripotent stem cells. *Cell Stem Cell*, 5(3), 237–241.
167. Mathieu, J., Zhang, Z., Zhou, W., et al. (2011). HIF induces human embryonic stem cell markers in cancer cells. *Cancer Research*, 71(13), 4640–4652.
168. Hama, A., Codogno, P., & Mehrpour, M. (2014). Cancer stem cells and autophagy: facts and perspectives. *Journal of Cancer Stem Cell Research*, 2, e1005.
169. Chen, Y., De Marco, M. A., Graziani, I., et al. (2007). Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. *Cancer Research*, 67(17), 7954–7959.
170. Bedogni, B., Warneke, J. A., Nickoloff, B. J., Giaccia, A. J., & Powell, M. B. (2008). Notch1 is an effector of Akt and hypoxia in melanoma development. *The Journal of Clinical Investigation*, 118(11), 3660–3670.
171. Hu, Y. Y., Fu, L. A., Li, S. Z., et al. (2014). Hif-1α and Hif-2α differentially regulate Notch signaling through competitive interaction with the intracellular domain of Notch receptors in glioma stem cells. *Cancer Letters*, 349(1), 67–76.
172. Gustafsson, M. V., Zheng, X., Pereira, T., et al. (2005). Hypoxia requires notch signaling to maintain the undifferentiated cell state. *Developmental Cell*, 9(5), 617–628.
173. D’Uva, G., Bertoni, S., Lauriola, M., et al. (2013). Beta-Catenin/HuR Post-transcriptional machinery governs cancer stem cell features in response to hypoxia. *PLoS ONE*, 8(11), e80742.
174. Mazumdar, J., O’Brien, W. T., Johnson, R. S., et al. (2010). O2 regulates stem cells through Wnt/β-catenin signalling. *Nature Cell Biology*, 12(10), 1007–1013.
175. Kaidi, A., Williams, A. C., & Paraskeva, C. (2007). Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. *Nature Cell Biology*, 9(2), 2010–2017.
176. Comerford, K. M., Wallace, T. J., Karhausen, J., Louis, N. A., Montalto, M. C., & Colgan, S. P. (2002). Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. *Cancer Research*, 62(12), 3387–3394.
177. Nishi, H., Nakada, T., Kyo, S., Inoue, M., Shay, J. W., & Isaka, K. (2004). Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT). *Molecular Cell Biology*, 24(13), 6076–6083.
178. Zhang, Y., Wang, H., Zhang, J., Lv, J., & Huang, Y. (2013). Positive feedback loop and synergistic effects between hypoxia-inducible factor-2α and stearoyl-CoA desaturase-1 promote tumorigenesis in clear cell renal cell carcinoma. *Cancer Science*, 104(4), 416–422.
179. Toschi, A., Lee, E., Gadir, N., Ohh, M., & Foster, D. A. (2008). Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. *The Journal of Biological Chemistry*, 283(50), 34495–34499.
180. Noto, A., Raffa, S., De Vitis, C., et al. (2013). Stearoyl-CoA desaturase-1 is a key factor for lung cancer-initiating cells. *Cell Death and Disease*, 4, e947.
181. Kim, R. J., Park, J. R., Roh, K. J., et al. (2013). High aldehyde dehydrogenase activity enhances stem cell features in breast cancer cells by activating hypoxia-inducible factor-2α. *Cancer Letters*, 333(1), 18–31.
182. Tiezzi, D. G., Clagnan, W. S., Mandarano, L. R., et al. (2013). Expression of aldehyde dehydrogenase after neoadjuvant chemotherapy is associated with expression of hypoxia-inducible factors 1 and 2 alpha and predicts prognosis in locally advanced breast cancer. *Clinics (S o Paulo, Brazil)*, 68(5), 592–598.
183. Jögi, A., Ora, I., Nilsson, H., et al. (2002). Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. *Proceedings of the National Academy of Sciences of the United States of America*, 99(10), 7021–7026.
184. Helczynska, K., Kronblad, A., Jögi, A., et al. (2003). Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. *Cancer Research*, 63(7), 1441–1444.

185. Liang, D., Ma, Y., Liu, J., et al. (2012). The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. *BMC Cancer*, 12, 201.
186. Zhang, H., Wu, H., Zheng, J., et al. (2013). Transforming growth factor β 1 signal is crucial for dedifferentiation of cancer cells to cancer stem cells in osteosarcoma. *Stem Cells*, 31(3), 433–446.
187. Kumar, S. M., Liu, S., Lu, H., et al. (2012). Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. *Oncogene*, 31(47), 4898–4911.
188. Jögi, A., Vaapil, M., Johansson, M., & Pahlman, S. (2012). Cancer cell differentiation heterogeneity and aggressive behavior in solid tumors. *Uppsala Journal of Medical Sciences*, 117(2), 217–224.
189. Axelson, H., Fredlund, E., Ovenberger, M., Landberg, G., & Pahlman, S. (2005). Hypoxia-induced dedifferentiation of tumor cells—a mechanism behind heterogeneity and aggressiveness of solid tumors. *Seminars in Cell and Developmental Biology*, 16(4–5), 554–563.
190. Marie-Egyptienne, D. T., Lohse, I., & Hill, R. P. (2013). Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. *Cancer Letters*, 341(1), 63–72.
191. Polyak, K., & Weinberg, R. A. (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. *Nature Reviews Cancer*, 9(4), 265–273.
192. Scheel, C., & Weinberg, R. A. (2012). Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. *Seminars in Cancer Biology*, 22(5–6), 396–403.
193. Singh, A., & Settleman, J. (2010). EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. *Oncogene*, 29(34), 4741–4751.
194. Dave, B., Mittal, V., Tan, N. M., & Chang, J. C. (2012). Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. *Breast Cancer Research*, 14(1), 202.
195. Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009). Epithelial-mesenchymal transitions in development and disease. *Cell*, 139(5), 871–890.
196. Jiang, J., Tang, Y. L., & Liang, X. H. (2011). EMT: a new vision of hypoxia promoting cancer progression. *Cancer Biology & Therapy*, 11(8), 714–723.
197. Morais, C., Johnson, D. W., Vesey, D. A., & Gobe, G. C. (2013). Functional significance of erythropoietin in renal cell carcinoma. *BMC Cancer*, 13, 14.
198. Hammers, H. J., Verheul, H. M., Salumbides, B., et al. (2010). Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. *Molecular Cancer Therapeutics*, 9(6), 1525–1535.
199. Krishnamachary, B., Zagzag, D., Nagasawa, H., et al. (2006). Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFH1A, and ZFH1B. *Cancer Research*, 66(5), 2725–2731.
200. Esteban, M. A., Tran, M. G., Harten, S. K., et al. (2006). Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. *Cancer Research*, 66(7), 3567–3575.
201. Evans, A. J., Russell, R. C., Roche, O., et al. (2007). VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. *Molecular and Cellular Biology*, 27(1), 157–169.
202. Huang, J., Yao, X., Zhang, J., et al. (2013). Hypoxia-induced downregulation of miR-30c promotes epithelial-mesenchymal transition in human renal cell carcinoma. *Cancer Science*, 104(12), 1609–1617.
203. Russell, R. C., & Ohh, M. (2007). The role of VHL in the regulation of E-cadherin: a new connection in an old pathway. *Cell Cycle*, 6(1), 56–59.
204. Sun, C., Song, H., Zhang, H., et al. (2012). CD133 expression in renal cell carcinoma (RCC) is correlated with nuclear hypoxia-inducing factor 1 α (HIF-1 α). *Journal of Cancer Research and Clinical Oncology*, 138(10), 1619–1624.
205. Valluru, M., Staton, C. A., Reed, M. W. R., & Brown, N. J. (2011). Transforming growth factor- β and endoglin signaling orchestrate wound healing. *Frontiers in Physiology*, 2, 89.
206. Barbara, N. P., Wrana, J. L., & Letarte, M. (1999). Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. *The Journal of Biological Chemistry*, 274(2), 584–594.
207. Oxmann, D., Held-Feindt, J., Stark, A. M., Hattermann, K., Yoneda, T., & Mentlein, R. (2008). Endoglin expression in metastatic breast cancer cells enhances their invasive phenotype. *Oncogene*, 27(25), 3567–3575.
208. Pardali, E., van der Schaft, D. W., Wiercinska, E., et al. (2011). Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma. *Oncogene*, 30(3), 334–345.
209. Sulzmaier, F. J., Jean, C., & Schlaepfer, D. D. (2014). FAK in cancer: mechanistic findings and clinical applications. *Nature Reviews Cancer*, 14(9), 598–610.
210. Yao, X. H., Ping, Y. F., & Bian, X. W. (2011). Contribution of cancer stem cells to tumor vasculogenic mimicry. *Protein & Cell*, 2(4), 266–272.
211. Fan, Y. L., Zheng, M., Tang, Y. L., & Liang, X. H. (2013). A new perspective of vasculogenic mimicry: EMT and cancer stem cells (Review). *Oncology Letters*, 6(5), 1174–1180.
212. Bussolati, B., Grange, C., & Camussi, G. (2011). Tumor exploits alternative strategies to achieve vascularization. *FASEB Journal*, 25(9), 2874–2882.
213. Zhang, Y., Sun, B., Zhao, X., et al. (2013). Clinical significances and prognostic value of cancer stem-like cells markers and vasculogenic mimicry in renal cell carcinoma. *Journal of Surgical Oncology*, 108(6), 414–419.
214. Pérez-Gómez, E., Del Castillo, G., Juan Francisco, S., López-Novoa, J. M., Bernabéu, C., & Quintanilla, M. (2010). The role of the TGF- β coreceptor endoglin in cancer. *The Scientific World Journal*, 10, 2367–2384.
215. Staller, P., Sulitkova, J., Lisztwan, J., Moch, H., Oakeley, E. J., & Krek, W. (2003). Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. *Nature*, 425(6955), 307–311.

221. Bindra, R. S., Vasselli, J. R., Stearman, R., Linehan, W. M., & Klausner, R. D. (2002). VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. *Cancer Research*, 62(11), 3014–3019.
222. Holmquist-Mengelbier, L., Fredlund, E., Löfstedt, T., et al. (2006). Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. *Cancer Cell*, 10(5), 413–423.
223. Noguera, R., Fredlund, E., Piqueras, M., et al. (2009). HIF-1alpha and HIF-2alpha are differentially regulated in vivo in neuroblastoma: high HIF-1alpha correlates negatively to advanced clinical stage and tumor vascularization. *Clinical Cancer Research*, 15(23), 7130–7136.
224. Helczynska, K., Larsson, A. M., Holmquist-Mengelbier, L., et al. (2008). Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer. *Cancer Research*, 68(22), 9212–9220.
225. Giatromanolaki, A., Koukourakis, M. I., Sivridis, E., et al. (2001). Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. *British Journal of Cancer*, 85(6), 881–890.
226. Kim, W. Y., Perera, S., Zhou, B., et al. (2009). HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. *The Journal of Clinical Investigation*, 119(8), 2160–2170.
227. Yang, M. H., Wu, M. Z., Chiou, S. H., et al. (2008). Direct regulation of TWIST by HIF-1alpha promotes metastasis. *Nature Cell Biology*, 10(3), 295–305.
228. Hoffmann, A. C., Mori, R., Vallbohmer, D., et al. (2008). High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF. *Neoplasia*, 10(7), 674–679.
229. Shen, C., & Kaelin, W. G., Jr. (2013). The VHL/HIF axis in clear cell renal carcinoma. *Seminars in Cancer Biology*, 23(1), 18–25.
230. Acker, T., Diez-Juan, A., Aragonés, J., et al. (2005). Genetic evidence for a tumor suppressor role of HIF-2alpha. *Cancer Cell*, 8(2), 131–141.
231. Bangoura, G., Liu, Z. S., Qian, Q., Jiang, C. Q., Yang, G. F., & Jing, S. (2007). Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma. *World Journal of Gastroenterology*, 13(23), 3176–3182.
232. Franovic, A., Holterman, C. E., Payette, J., & Lee, S. (2009). Human cancers converge at the HIF-2alpha oncogenic axis. *Proceedings of the National Academy of Sciences of the United States of America*, 106(50), 21306–21311.
233. Mandriota, S. J., Turner, K. J., Davies, D. R., et al. (2002). HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. *Cancer Cell*, 1(5), 459–468.
234. Kondo, K., Klcio, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G., Jr. (2002). Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. *Cancer Cell*, 1(3), 237–246.
235. Kondo, K., Kim, W. Y., Lechpammer, M., & Kaelin, W. G., Jr. (2003). Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. *PLoS Biology*, 1(3), E83.
236. Covello, L., Simon, M. C., & Keith, B. (2005). Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. *Cancer Research*, 65(6), 2277–2286.
237. Maranchie, J. K., Vasselli, J. R., Riss, J., Bonifacino, J. S., Linehan, W. M., & Klausner, R. D. (2002). The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. *Cancer Cell*, 1(3), 247–255.
238. Raval, R. R., Lau, K. W., Tran, M. G., et al. (2005). Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. *Molecular and Cellular Biology*, 25(13), 5675–5686.
239. Zimmer, M., Doucette, D., Siddiqui, N., & Iliopoulos, O. (2004). Inhibition of hypoxia-inducible factor is sufficient for growth suppression of Vhl^{-/-} tumors. *Molecular Cancer Research*, 2(2), 89–95.
240. Hu, C. J., Wang, L. Y., Chodosh, L. A., Keith, B., & Simon, M. C. (2003). Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. *Molecular and Cellular Biology*, 23(24), 9361–9374.
241. Brown, J. M., & Wilson, W. R. (2004). Exploiting tumour hypoxia in cancer treatment. *Nature Reviews Cancer*, 4(6), 437–447.
242. Baldewijns, M. M. (2010). VHL and HIF signalling in renal cell carcinogenesis. *Journal of Pathology*, 221(2), 125–138.
243. Gilbertson, R. J., & Rich, J. N. (2007). Making a tumour's bed: glioblastoma stem cells and the vascular niche. *Nature Reviews Cancer*, 7(10), 733–736.
244. Czarnecka, A. M., & Szczylik, C. (2013). Renal cell carcinoma cancer stem cells as therapeutic targets. *Current Signal Transduction Therapy*, 8(3), 203–209.
245. Bielecka, Z. F., Czarnecka, A. M., & Szczylik, C. (2014). Genomic analysis as the first step toward personalized treatment in renal cell carcinoma. *Frontiers in Oncology*, 4, 194.
246. Kanesvaran, R., & Tan, M. H. (2014). Targeted therapy for renal cell carcinoma: the next lap. *Journal of Carcinogenesis*, 13, 3.
247. Crea, F., Duhagon, M. A., Farrar, W. L., & Danesi, R. (2011). Pharmacogenomics and cancer stem cells: a changing landscape? *Trends in Pharmacological Sciences*, 32(8), 487–494.
248. Azzi, S., Bruno, S., Giron-Michel, J., et al. (2011). Differentiation therapy: targeting human renal cancer stem cells with interleukin 15. *Journal of the National Cancer Institute*, 103(24), 1884–1898.
249. Ziebarth, A. J., Nowsheen, S., Steg, A. D., et al. (2013). Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. *Clinical Cancer Research*, 19(1), 170–182.
250. Fried, L. E., & Arbiser, J. L. (2009). Honokiol, a multifunctional antiangiogenic and antitumor agent. *Antioxidants & Redox Signaling*, 11(5), 1139–1148.
251. Li, W., Wang, Q., Su, Q., et al. (2014). Honokiol suppresses renal cancer cells' metastasis via dual-blocking epithelial-mesenchymal transition and cancer stem cell properties through modulating miR-141/ZEB2 signaling. *Molecules and Cells*, 37(5), 383–388.
252. Banerjee, P., Basu, A., Arbiser, J. L., & Pal, S. (2013). The natural product honokiol inhibits calcineurin inhibitor-induced and Ras-mediated tumor promoting pathways. *Cancer Letters*, 338(2), 292–299.
253. von Roemeling, C. A., Marlow, L. A., Wei, J. J., et al. (2013). Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. *Clinical Cancer Research*, 19(9), 2368–2380.
254. Sourbier, C., Srivastava, G., Ghosh, M. C., et al. (2012). Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma. *Oncotarget*, 3(11), 1472–1482.
255. Buczek, M., Escudier, B., Bartnik, E., Szczylik, C., & Czarnecka, A. (2014). Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms. *Biochimica et Biophysica Acta*, 1845(1), 31–41.
256. Porta, C., Szczylik, C., & Escudier, B. (2012). Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review. *Critical Reviews in Oncology/Hematology*, 82(3), 323–337.
257. Joosten, S. C., Hamming, L., Soetekouw, P. M., et al. (2014). Resistance to sunitinib in renal cell carcinoma: from molecular mechanisms to predictive markers and future perspectives. *Biochimica et Biophysica Acta*, 1855(1), 1–16.

258. Ravaud, A., & Gross-Goupil, M. (2012). Overcoming resistance to tyrosine kinase inhibitors in renal cell carcinoma. *Cancer Treatment Reviews*, 38(8), 996–1003.
259. Bergers, G., & Hanahan, D. (2008). Modes of resistance to anti-angiogenic therapy. *Nature Reviews Cancer*, 8(8), 592–603.
260. Rini, B. I., & Atkins, M. B. (2009). Resistance to targeted therapy in renal-cell carcinoma. *Lancet Oncology*, 10(10), 992–1000.
261. D’Alterio, C., Portella, L., & Ottaiano, A. (2012). High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer. *Current Cancer Drug Targets*, 12(6), 693–702.
262. Conley, S. J., Gheordunescu, E., Kakarala, P., et al. (2012). Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. *Proceedings of the National Academy of Sciences of the United States of America*, 109(8), 2784–2789.
263. Shen, R., Ye, Y., Chen, L., Yan, Q., Barsky, S. H., & Gao, J. X. (2008). Precancerous stem cells can serve as tumor vasculogenic progenitors. *PLoS ONE*, 3(2), e1652.
264. Brossa, A., Grange, C., Mancuso, L., et al. (2015). Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation. *Oncotarget*, 6(13), 11295–11309.
265. Bousquet, G., & Janin, A. (2015). Reactive resistance to anti-angiogenic drugs. *Aging (Albany NY)*, 7(5), 282–283.
266. Kieda, C., El Hafny-Rahbi, B., Collet, G., et al. (2013). Stable tumor vessel normalization with pO₂ increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment. *Journal of Molecular Medicine (Berlin, Germany)*, 91(7), 883–899.
267. Collet, G., Lamerant-Fayel, N., Tertilt, M., et al. (2014). Hypoxia-regulated overexpression of soluble VEGFR2 controls angiogenesis and inhibits tumor growth. *Molecular Cancer Therapeutics*, 13(1), 165–178.
268. Lin, F., Wang, N., & Zhang, T. C. (2012). The role of endothelial-mesenchymal transition in development and pathological process. *International Union of Biochemistry and Molecular Biology Life*, 64(9), 717–723.